

chain nodes :

42 44 46 47 48

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
33 34 35 36

chain bonds :

4-48 8-48 14-46 44-46 46-47

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-15 15-16 16-17 17-18 19-20
19-24 20-21 21-22 22-23 23-24 25-26 25-30 26-27 27-28 28-29 29-30 31-32 31-36 32-33 33-34 34-35 35-36

exact/norm bonds :

4-48 8-48 44-46 46-47

exact bonds :

14-46

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-15 15-16 16-17 17-18 19-20
19-24 20-21 21-22 22-23 23-24 25-26 25-30 26-27 27-28 28-29 29-30 31-32 31-36 32-33 33-34 34-35 35-36

isolated ring systems :

containing 1 : 7 : 13 : 19 : 25 : 31 :


G1:[*1],[*2],[*3]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom
15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom
28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 42:CLASS43:Atom 44:CLASS45:Atom
46:CLASS

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2025	((544/324) or (514/275)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/10/01 04:18



chain nodes :

42 44 45 46 47 48 50

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
33 34 35 36

chain bonds :

4-47 8-47 12-44 14-45 44-45 45-46 48-50

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-15 15-16 16-17 17-18 19-20
19-24 20-21 21-22 22-23 23-24 25-26 25-30 26-27 27-28 28-29 29-30 31-32 31-36 32-33 33-34 34-35 35-36

exact/norm bonds :

4-47 8-47 12-44 44-45 45-46 48-50

exact bonds :

14-45

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-15 15-16 16-17 17-18 19-20
19-24 20-21 21-22 22-23 23-24 25-26 25-30 26-27 27-28 28-29 29-30 31-32 31-36 32-33 33-34 34-35 35-36

isolated ring systems :

containing 1 : 7 : 13 : 19 : 25 : 31 :

G1:[*1],[*2],[*3]


Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom
15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom
28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 42:CLASS43:Atom 44:CLASS45:CLASS
46:CLASS

11/561,039

RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>
Uploading C:\Program Files\Stnexp\Queries\10528913.str



```

chain nodes :
42 44 46 47
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 31 32 33 34 35 36
chain bonds :
4-8 14-46 44-46 46-47
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23 23-24 25-26 25-30
26-27 27-28 28-29 29-30 31-32 31-36 32-33 33-34 34-35 35-36
exact/norm bonds :
44-46 46-47
exact bonds :
4-8 14-46
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23 23-24 25-26 25-30
26-27 27-28 28-29 29-30 31-32 31-36 32-33 33-34 34-35 35-36
isolated ring systems :
containing 1 : 7 : 13 : 19 : 25 : 31 :

G1:[*1], [*2], [*3]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:Atom 32:Atom 33:Page 134:Atom 35:Atom 36:Atom 42:CLASS
43:Atom 44:CLASS 45:Atom 46:CLASS 47:CLASS

```


L1 STRUCTURE uploaded

=> d l1
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 02:41:49 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 241 TO ITERATE

100.0% PROCESSED 241 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3889 TO 5751
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=>
Uploading C:\Program Files\Stnexp\Queries\10528913 (a).str



chain nodes :

42 44 46 47 48

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 31 32 33 34 35 36

chain bonds :

4-48 8-48 14-46 44-46 46-47

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23 23-24 25-26 25-30
26-27 27-28 28-29 29-30 31-32 31-36 32-33 33-34 34-35 35-36

exact/norm bonds :

4-48 8-48 44-46 46-47

exact bonds :

14-46

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23 23-24 25-26 25-30
26-27 27-28 28-29 29-30 31-32 31-36 32-33 33-34 34-35 35-36

isolated ring systems :

containing 1 : 7 : 13 : 19 : 25 : 31 :

G1:[*1], [*2], [*3]

Match level :

1:Atom	2:Atom	3:Atom	4:Atom	5:Atom	6:Atom	7:Atom	8:Atom	9:Atom	10:Atom
11:Atom	12:Atom	13:Atom	14:Atom	15:Atom	16:Atom	17:Atom	18:Atom	19:Atom	
20:Atom	21:Atom	22:Atom	23:Atom	24:Atom	25:Atom	26:Atom	27:Atom	28:Atom	
29:Atom	30:Atom	31:Atom	32:Atom	33:Atom	34:Atom	35:Atom	36:Atom	42:CLASS	
43:Atom	44:CLASS	45:Atom	46:CLASS	4Page	3S	48:CLASS			

L3 STRUCTURE UPLOADED

=> d 13
L3 HAS NO ANSWERS
L3 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 13 sss sam
SAMPLE SEARCH INITIATED 02:43:25 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 295 TO ITERATE

100.0% PROCESSED 295 ITERATIONS 18 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 4870 TO 6930
PROJECTED ANSWERS: 106 TO 614


L4 18 SEA SSS SAM L3

=> => s 13 sss ful
FULL SEARCH INITIATED 02:49:19 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 6155 TO ITERATE

100.0% PROCESSED 6155 ITERATIONS 460 ANSWERS
SEARCH TIME: 00.00.01

L5 460 SEA SSS FUL L3

=>
Uploading C:\Program Files\Stnexp\Queries\10528913 (sub).str



chain nodes :
 42 44 45 46 47 48 50
 ring nodes :
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
 24 25 26 27 28 29 30 31 32 33 34 35 36
 chain bonds :
 4-47 8-47 12-44 14-45 44-45 45-46 48-50
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
 14-15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23 23-24 25-26 25-30
 26-27 27-28 28-29 29-30 31-32 31-36 32-33 33-34 34-35 35-36
 exact/norm bonds :
 4-47 8-47 12-44 44-45 45-46 48-50
 exact bonds :
 14-45
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
 14-15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23 23-24 25-26 25-30
 26-27 27-28 28-29 29-30 31-32 31-36 32-33 33-34 34-35 35-36
 isolated ring systems :
 containing 1 : 7 : 13 : 19 : 25 : 31 :

G1:[*1],[*2],[*3]

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 42:CLASS
 43:Atom 44:CLASS 45:CLASS 46:CLASS 47:CLASS 48:CLASS 49:Atom 50:Atom
 Page 5

L6 STRUCTURE UPLOADED

=> d 16
L6 HAS NO ANSWERS
L6 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 16 sss sub=15 sam
SAMPLE SUBSET SEARCH INITIATED 02:51:06 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED - 17 TO ITERATE

100.0% PROCESSED 17 ITERATIONS 9 ANSWERS
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):	ONLINE	**COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):	93 TO	587
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):	9 TO	360

L7 9 SEA SUB=L5 SSS SAM L6

=> => s 16 sss sub=15 ful
FULL SUBSET SEARCH INITIATED 02:51:42 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 410 TO ITERATE

100.0% PROCESSED 410 ITERATIONS 194 ANSWERS
SEARCH TIME: 00.00.01


L8 194 SEA SUB=L5 SSS FUL L6

=> s 15 not 18
L9 266 L5 NOT L8


=> => s 19
L10 51 L9

=> d 110 1-51 bib,ab,hitstr


L10 ANSWER 1 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2007:746469 CAPLUS
 DN 147:202995
 TI Optimization of novel combi-molecules: Identification of balanced and mixed bcr-abl/DNA targeting properties
 AU Rachid, Zakaria; Katsoulas, Athanasia; Williams, Christopher; Larroque, Anne-Laure; McNamee, James; Jean-Claude, Bertrand J.
 CS Chemical Computing Group Inc., Montreal, QC, H3A 2R7, Can.
 SO Bioorganic & Medicinal Chemistry Letters (2007), 17(15), 4248-4253
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Ltd.
 DT Journal
 LA English
 AB Steps toward the identification of combi-mols. with strong abl tyrosine kinase (TK) inhibitory property and significant DNA damaging potential are described. The optimized combi-mol. (I) was shown to induce approx. twofold stronger abl TK inhibitory activity than Gleevec and high levels of DNA damage in chronic myelogenous leukemic cells.
 IT 623901-01-9P 945028-65-9P
 RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (bcr-abl/DNA targeting compds.)
 RN 623901-01-9 CAPLUS
 CN Benzamide, 4-amino-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 945028-65-9 CAPLUS
 CN Benzamide, 4-amino-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




IT 945028-55-7P 945028-58-0P 945028-59-1P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (bcr-abl/DNA targeting compds.)
 RN 945028-55-7 CAPLUS
 CN Benzamide, 4-[bis(2-chloroethyl)amino]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 945028-58-0 CAPLUS

CN Benzamide, 4-[(bis(2-chloroethyl)amino)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)



RN 945028-59-1 CAPLUS

CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-(3-methyl-2-triazen-1-yl)-3-(trifluoromethyl)- (CA INDEX NAME)



IT 623901-04-2P 945028-57-9P 945028-60-4P


945028-61-5P 945028-62-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(bcr-abl/DNA targeting compds.)


RN 623901-04-2 CAPLUS

CN Benzamide, 4-[(3-hydroxymethyl-1-triazenyl)-3-methyl-1-triazenyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 945028-57-9 CAPLUS


CN Benzamide, 4-[(2-chloroethyl)methylamino)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 945028-60-4 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 945028-61-5 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 945028-62-6 CAPLUS
 CN Benzamide, 3-chloro-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinylamino]phenyl]-4-(3-methyl-2-triazen-1-yl)- (CA INDEX NAME)




IT 404844-11-7P 945028-56-8P 945028-63-7P
 945028-64-8P 945028-66-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (bcr-abl/DNA targeting compds.)
 RN 404844-11-7 CAPLUS
 CN Benzamide, 4-(chloromethyl)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinylamino]phenyl]- (CA INDEX NAME)




RN 945028-56-8 CAPLUS
 CN Benzamide, 4-[(2-hydroxyethyl)methylamino]methyl-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 945028-63-7 CAPLUS
 CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-nitro-3-(trifluoromethyl)- (CA INDEX NAME)



RN 945028-64-8 CAPLUS
 CN Benzamide, 3-chloro-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-nitro- (CA INDEX NAME)




RN 945028-66-0 CAPLUS
 CN Benzamide, 4-amino-3-chloro-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2007:653891 CAPLUS
 DN 147:227100
 TI Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cells
 AU Gonzalo, Teresa; Beljaars, Leonie; van de Bovenkamp, Marja; Temming, Kai; van Loenen, Anne-Miek; Reker-Smit, Catharina; Meijer, Dirk K. F.; Lacombe, Marie; Opdam, Frank; Keri, Gyoergy; Oerfi, Laszlo; Poelstra, Klaas; Kok, Robbert J.
 CS Department of Pharmacokinetics and Drug Delivery, Groningen University Institute for Drug Exploration, University of Groningen, Neth.
 SO Journal of Pharmacology and Experimental Therapeutics (2007), 321(3), 856-865
 CODEN: JPETAB; ISSN: 0022-3565
 PB American Society for Pharmacology and Experimental Therapeutics
 DT Journal
 LA English
 AB Liver fibrosis is characterized by excessive proliferation and activation of hepatic stellate cells (HSC), a process in which platelet-derived growth factor (PDGF) plays an important role. Inhibition of liver fibrosis via specific delivery of a PDGF kinase inhibitor to HSC might therefore be an attractive strategy. The HSC-selective carrier mannose-6-phosphate modified human serum albumin (M6PHSA) was equipped with a tyrosine kinase inhibitor, 4-chloro-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]- benzamide (PAP19) (an imatinib derivative), by means of the platinum-based universal linkage system (ULS). The antifibrotic activity of PAP19-M6PHSA was evaluated in culture-activated rat HSC and precision-cut liver slices from fibrotic rats. After 24-h incubation, both free inhibitor PAP19 and PAP19-M6PHSA showed potent activity, as determined by quant. reverse transcription-polymerase chain reaction anal. of α -smooth muscle actin (α SMA) and procollagen 1a1. Next, we examined the organ distribution and antifibrotic activity of PAP19-M6PHSA in bile duct-ligated (BDL) rats. Male Wistar rats at day 10 after BDL were administered a single dose of PAP19-M6PHSA and sacrificed at 2 h, 1 day, or 2 days afterward. The accumulation of PAP19-M6PHSA in the liver was quantified by high-performance liquid chromatog. anal. (30% of the injected dose at 2 h) and detected in the liver by staining of the carrier. Liver drug levels were sustained at 24 and 48 h after the single dose. Furthermore, PAP19-M6PHSA reduced collagen deposition (Sirius red staining) and α SMA staining of activated HSC at these time points in comparison with saline-treated rats. We therefore conclude that delivery of a PDGF-kinase inhibitor to HSC is a promising technol. to attenuate liver fibrogenesis.
 IT 945493-73-2DP, PAP 19, conjugate with human serum albumin
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (local inhibition of liver fibrosis by specific delivery of platelet-derived growth factor kinase inhibitor to hepatic stellate cells)
 RN 945493-73-2 CAPLUS
 CN Benzamide, 4-chloro-N-[4-methyl-3-[[5-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)

10/528, 913



RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2007:418588 CAPLUS
 DN 147:257793
 TI Preparation of the imatinib
 IN Kompella, Amala; Srinivas, Rachakonda; Rao, Adibhatla Kali Satya Bhujanga;
 Nannapaneni, Venkaiah Chowdary
 PA Natco Pharma Limited, India
 SO Indian Pat. Appl., 33pp.
 CODEN: INXXBQ
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI IN 2003MA00462	A	20070209	IN 2003-MA462	20030606
PRAI IN 2003-MA462		20030606		
OS CASREACT 147:257793				

AB A process for the preparation of title compound I was disclosed. For example, N-alkylation of N-methylpiperazine with benzyl chloride II afforded title compound I in 61% yield. Of note, purification via column chromatog. is avoided


at all stages in the preparation of title compound I.

IT 404844-11-7P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of the imatinib)

RN 404844-11-7 CAPLUS

CN Benzamide, 4-(chloromethyl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



Ar
NH₂
NH₂

L10 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2007:150876 CAPLUS
 DN 146:185242
 TI Triflusal-containing polymers for stent coating
 IN San Roman Del Barrio, Julio; Rodriguez-Crespo, Gema; Fernandez-Gutierrez, Mar; Gallardo-Ruiz, Alberto; Duocastella-Codina, Luis; Molina-Crisol, Maria
 PA J. Uriach Y Compania S.A., Spain
 SO PCT Int. Appl., 20pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007014787	A1	20070208	WO 2006-EP9156	20060920
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1767552	A1	20070328	EP 2005-380204	20050921
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				

PRAI EP 2005-380204 A 20050921


AB New triflusal-containing polymeric compds. resulting from the polymerization of 2-(methacryloyloxy)ethyl 2-acetyloxy-4-(trifluoromethyl)benzoate with Bu acrylate are described. These new polymers exhibit good adhesion and crack-bridging properties and are particularly suitable for the coating of stents.

IT 152459-94-4, CGP-53716

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (triflusal-containing polymers for stent coating)

RN 152459-94-4 CAPLUS


CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (CA INDEX NAME)




RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:1337398 CAPLUS
 DN 146:81891
 TI Process for preparation of isotopically labeled imatinib and intermediates
 IN Salter, Rhys; Rodriguez Perez, Maria Ines; Moenius, Thomas; Voges, Rolf;
 Andres, Hendrik; Bordeaux, Kirk
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SO PCT Int. Appl., 36pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006133904	A2	20061221	WO 2006-EP5676	20060613
	WO 2006133904	A3	20070322		
		W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
		RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
PRAI	GB 2005-12091	A	20050614		
OS	MARPAT 146:81891				
AB	This invention relates to a new process for preparation of isotopically labeled imatinib and intermediates. For example, 4-chloromethyl-N-[4-methyl-3-[4-(1-oxido-3-pyridinyl)-[2-14C]-pyrimidin-2-ylamino]phenyl]benzamide hydrochloride (preparation given) was reacted with 1-methylpiperazine in ethanol, followed by the addition of methanesulfonic acid to give methanesulfonate of I [X = 14C]. Isotopically labeled intermediates were also described.				
IT	404844-11-7	917358-62-4	917358-64-6		
RL	RCT (Reactant); RACT (Reactant or reagent) (preparation of isotopically labeled imatinib and intermediates)				
RN	404844-11-7	CAPLUS			
CN	Benzamide, 4-(chloromethyl)-N-[4-methyl-3-[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)				




RN 917358-62-4 CAPLUS
 CN Benzamide, 4-(chloromethyl)-N-[4-methyl-3-[4-(1-oxido-3-pyridinyl)-2-pyrimidinyl-2-14C]amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 917358-64-6 CAPLUS

CN Benzamide, 4-(chloromethyl)-N-[4-methyl-3-[(4-(1-oxido-3-pyridinyl)-2-pyrimidinyl-2-14C)amino]phenyl]- (CA INDEX NAME)



L10 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:1013769 CAPLUS

DN 145:356807

TI Method for preparation of 4-pyridine-3-yl-2-[4-methyl-3-(benzamido)phenylamino]pyrimidine derivatives and application as pharmaceutical compositions

IN Zheng, Shu; Xu, Rongzhen; Chen, Hongxiang

PA Hangzhou New Rayjay Biomed Corporation, Peop. Rep. China

SO Faming Zhanli Shenqing Gongkai Shuomingshu, 19pp.

CODEN: CNXXEV

DT Patent

LA Chinese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1706840	A	20051214	CN 2004-10009181	20040607
PRAI	CN 2004-10009181		20040607		
OS	CASREACT 145:356807; MARPAT 145:356807				

AB The title derivs. have the general formula I (R1 to R7 = H, C1-C4 alkyl, lower alkyl substituted by -OH, -COR8, -CN, or -CONH2; R8 = C1-C4 alkyl, cycloalkyl, or cycloalkyl substituted by OH; and X = C1-C4 alkylene, -NHCO-, or -OCO-). Their preparation method comprises reacting 4-chloromethylbenzoyl chloride with 2-(5-aminophenylamino)-4-pyridine-3-yl-pyrimidine derivative to obtain N-[3-(4-pyridine-3-yl-pyrimidin-2-amino)phenyl]-4-chloromethylbenzamide derivative, then reacting with piperazine to generate title derivative hydrochloride, further reacting with methanesulfonic acid to obtain the final product. The claimed compds. can be used for treating leukemia and tumor, which have remarkable inhibiting effect on the growth of leukocyte in peripheral blood of leukemia patients. The claimed compds. can constitute compns. with pharmaceutically-acceptable adjuvants, and effective amount of one or more other known antileukemia or antitumor medicines for treating leukemia and tumor to reach synergistic effect.


IT 404844-11-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of pyridinyl[methyl(benzamido)phenylamino]pyrimidine derivs. and application for treating leukemia)

RN 404844-11-7 CAPLUS

CN Benzamide, 4-(chloromethyl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



L10 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:735123 CAPLUS
 DN 146:223251
 TI A General Strategy for Creating "Inactive-Conformation" Abl Inhibitors
 AU Okram, Barun; Nagle, Advait; Adrian, Francisco J.; Lee, Christian; Ren, Pingda; Wang, Xia; Sim, Taebo; Xie, Yongping; Wang, Xing; Xia, Gang; Spraggon, Glen; Warmuth, Markus; Liu, Yi; Gray, Nathanael S.
 CS Department of Chemistry and the Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA
 SO Chemistry & Biology (Cambridge, MA, United States) (2006), 13(7), 779-786
 CODEN: CBOLE2; ISSN: 1074-5521
 PB Cell Press
 DT Journal
 LA English
 AB Summary: Kinase inhibitors that bind to the ATP cleft can be broadly classified into two groups: Those that bind exclusively to the ATP site with the kinase assuming a conformation otherwise conducive to phosphotransfer (type I), and those that exploit a hydrophobic site immediately adjacent to the ATP pocket made accessible by a conformational rearrangement of the activation loop (type II). To date, all type II inhibitors were discovered by using structure-activity-guided optimization strategies. Here, we describe a general pharmacophore model of type II inhibition that enables a rational "hybrid-design" approach whereby a 3-trifluoromethylbenzamide functionality is appended to four distinct type I scaffolds in order to convert them into their corresponding type II counterparts. We demonstrate that the designed compds. function as type II inhibitors by using biochem. and cellular kinase assays and by cocrystallog. with Abl.
 IT 879507-24-1P
 RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and inhibition of Abl, tyrosine and serine/threonine kinases by inactive-conformation Abl inhibitors)
 RN 879507-24-1 CAPLUS
 CN Benzamide, N-[4-methyl-3-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)



RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:656689 CAPLUS
 DN 145:103728
 TI A process for preparation of imatinib base
 IN Szczepk, Wojciech; Luniewski, Wojciech; Kaczmarek, Lukasz; Zagrodzki, Bogdan; Samson-Lazinska, Dorota; Szelejewski, Wieslaw; Skarzynski, Maciej
 PA Instytut Farmaceutyczny, Pol.
 SO PCT Int. Appl., 37 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006071130	A2	20060706	WO 2005-PL88	20051230
	WO 2006071130	A3	20060928		
	W: AE, AG, AL, AM, AT, AU, AZ	BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1833815	A2	20070919	EP 2005-822030	20051230
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
PRAI	PL 2004-372016	A	20041230		
	PL 2005-376691	A	20050819		
	PL 2005-377984	A	20051108		
	WO 2005-PL88	W	20051230		

OS CASREACT 145:103728


AB The invention provides an improved process for preparation of imatinib base and its pharmaceutically-acceptable acid addition salts [imatinib is 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide]. The process involves reduction of N-(5-nitro-2-methylphenyl)-4-(3-pyridinyl)-2-pyrimidinamine (I) using hydrazine in the presence of Raney nickel, followed by condensation with 4-(chloromethyl)benzoyl chloride and then N-methylpiperazine. Compound I was obtained by reaction of 1-(2-methyl-5-nitrophenyl)guanidine nitrate (prepared from 2-methyl-5-nitroaniline and cyanamide) with 3-(dimethylamino)-1-(3-pyridinyl)prop-2-en-1-one (prepared from 3-acetylpyridine and DMF di-Me acetal).

IT 404844-11-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (process for preparation of imatinib base)

RN 404844-11-7 CAPLUS

CN Benzamide, 4-(chloromethyl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



L10 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:333442 CAPLUS

DN 144:370121

TI Preparation of pyrimidine derivatives as phosphatase and kinase inhibitors for treating a variety of diseases

IN Klebl, Bert; Baumann, Matthias; Hoppe, Edmund; Brehmer, Dirk; Daub, Henrik; Keri, Gyoergy; Varga, Zoltan; Marosfalvi, Jenoe; Oerfi, Laszlo

PA GPC Biotech A.-G., Germany

SO PCT Int. Appl., 100 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006021458	A2	20060302	WO 2005-EP9291	20050829
	WO 2006021458	A3	20070412		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CX, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	CA 2578122	A1	20060302	CA 2005-2578122	20050829
	EP 1786781	A2	20070523	EP 2005-785583	20050829
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				

PRAI US 2004-604685P P 20040827

WO 2005-EP9291 W 20050829

OS MARPAT 144:370121

AB The present invention relates to pyrimidine derivs. of general formula I (wherein R and R* = CH₃, C₂H₅, R', R¹⁷; R' = H, F, Cl, CN, OCF₃, NH₂, SH, etc.; R¹⁷ = H, R', CH₃, C₂H₅, CH=CH₂, etc.; Z = NH-CO-R⁵, CO-NH-R⁵, NH-CS-R⁵, etc. or a substituted ring or ring system; R⁵ = H, R⁴, CH₂R³, etc. or a substituted ring, e.g., Ph, naphthyl; R³, R⁴ = H, OH, SH, heterocyclic ring, etc.; X = a substituted ring or ring system), methods for their synthesis, and the use of said pyrimidine derivs. as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferation disorders, cancer, leukemia, erectile dysfunction, cardiovascular diseases and disorders, inflammatory diseases, transplant rejection, immunol. diseases, neuroimmunol. diseases, autoimmune diseases, infective diseases including opportunistic infections, prion diseases and/or neuro-degeneration. I are inhibitors of phosphatase and kinase, specifically selected from Abl, Akt, c-kit, EGF-R, GSK3b, JNK, Lck, PDGF-R, PknG, and ROCK2. Furthermore, the present invention relates to pharmaceutical compns. containing at least one pyrimidine derivative and/or pharmaceutically acceptable salts thereof as an active ingredient together with at least one pharmaceutically acceptable carrier, excipient or diluents as well as to methods for prophylaxis and/or treatment of the above-mentioned diseases and disorders. For example, II was prepared from the appropriate amine and appropriate benzoyl chloride. G315The I that were tested were able to inhibit the amount of pathogenic prion protein PrPSc in infected cells at concentration between 5 and 20 μM. A method for

detecting prion infections and/or prion diseases in a sample is also claimed, the method comprises administering I to a sample and detecting activity in said sample of the human cellular protein kinase Abl.

IT 152459-76-2P, 4-Chloro-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 152459-86-4P, 2-Methoxy-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 152459-88-6P, 4-Cyano-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 152459-91-1P, 4-Methyl-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 152459-92-2P, 4-Chloro-N-[3-[[4-(pyridin-4-yl)pyrimidin-2-yl]amino]phenyl]benzamide 152459-94-4P, N-[4-Methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 152459-96-6P, 4-Methyl-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 152459-98-8P, 4-Chloro-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 152459-99-9P*
** , 2-Methoxy-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide ***404844-11-7P, 4-Chloromethyl-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-06-5P, 4-Chloromethyl-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-08-7P, 3,4,5-Trimethoxy-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-09-8P, 4-Methoxy-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-12-3P, 3,5-Dimethoxy-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-13-4P, 3,4,5-Trimethoxy-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-14-5P, 4-Cyano-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-15-6P, 4-Methoxy-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-18-9P, 3,5-Dimethoxy-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-19-0P, N-[4-Methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]-4-trifluoromethoxybenzamide 475587-25-8P, 3,4,5-Trimethoxy-N-[4-methyl-3-[[4-(pyridin-2-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-26-9P, 4-Cyano-N-[4-methyl-3-[[4-(pyridin-2-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-27-0P, 4-Chloro-N-[4-methyl-3-[[4-(pyridin-2-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-29-2P, 4-Cyano-N-[4-methyl-3-[[4-(pyridin-4-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-31-6P, 4-Methoxy-N-[4-methyl-3-[[4-(pyridin-4-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-32-7P, 4-Chloro-N-[4-methyl-3-[[4-(pyridin-4-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-34-9P, 3,5-Dimethoxy-N-[3-[[4-(pyridin-4-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-38-3P, N-[4-Methyl-3-[[4-(pyridin-4-yl)pyrimidin-2-yl]amino]phenyl]-4-trifluoromethoxybenzamide 475587-40-7P, 4-Methoxy-N-[3-[[4-(pyridin-4-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-41-8P, 4-Cyano-N-[3-[[4-(pyridin-4-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-42-9P, 3,4,5-Trimethoxy-N-[3-[[4-(pyridin-4-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-43-0P, 3,5-Dimethoxy-N-[4-methyl-3-[[4-(pyridin-4-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-44-1P, 3,4,5-Trimethoxy-N-[4-methyl-3-[[4-(pyridin-4-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-46-3P, 4-Methoxy-N-[4-methyl-3-[[4-(pyridin-2-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-47-4P, 3,5-Dimethoxy-N-[4-methyl-3-[[4-(pyridin-2-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-48-5P, N-[3-[[4-(Pyridin-4-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-49-6P, 4-Chloro-N-[3-[[4-(pyridin-2-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-50-9P, 4-Methoxy-N-[3-[[4-(pyridin-2-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-57-6P, 4-Cyano-N-[3-[[4-(pyridin-2-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-58-7P, 3,5-Dimethoxy-N-[3-[[4-

(pyridin-2-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-59-8P
, 4-Bromo-N-[3-[[4-(pyridin-2-yl)pyrimidin-2-yl]amino]phenyl]benzamide
475587-60-1P, 4-Methyl-N-[3-[[4-(pyridin-2-yl)pyrimidin-2-
yl]amino]phenyl]benzamide 475587-62-3P, 3,5-Dichloro-N-[3-[[4-
(pyridin-2-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-63-4P
, N-[3-[[4-(Pyridin-2-yl)pyrimidin-2-yl]amino]phenyl]benzamide
475587-64-5P, 4-Chloromethyl-N-[3-[[4-(pyridin-2-yl)pyrimidin-2-
yl]amino]phenyl]benzamide 475587-72-5P, 2-Methoxy-N-[3-[[4-
(pyridin-4-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-73-6P
, N-[3-[[4-(Pyridin-4-yl)pyrimidin-2-yl]amino]phenyl]-4-
trifluoromethoxybenzamide 475587-74-7P, 4-Methyl-N-[3-[[4-
(pyridin-4-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-70-0P
, 4-Chloromethyl-N-[4-[[4-(pyridin-3-yl)pyrimidin-2-
yl]amino]phenyl]benzamide 881673-97-8P, N-[4-[[4-(Pyridin-3-
yl)pyrimidin-2-yl]amino]phenyl]benzamide 881674-08-4P,
4-Cyano-N-[4-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
881674-14-2P, 3,4,5-Trimethoxy-N-[4-[[4-(pyridin-3-yl)pyrimidin-2-
yl]amino]phenyl]benzamide 881674-18-6P, 2-Methoxy-N-[4-[[4-
(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 881674-19-7P
, 4-Methyl-N-[4-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
881674-23-3P, 4-Cyano-N-[4-[[4-(pyridin-4-yl)pyrimidin-2-
yl]amino]phenyl]benzamide 881674-24-4P, 4-Chloromethyl-N-[4-[[4-
(pyridin-4-yl)pyrimidin-2-yl]amino]phenyl]benzamide 881674-26-6P
, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-[[4-(pyridin-3-yl)pyrimidin-2-
yl]amino]phenyl]benzamide 881674-28-8P, 4-Chloro-N-[4-[[4-
(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 881674-32-4P
, 3,4,5-Trimethoxy-N-[4-[[4-(pyridin-2-yl)pyrimidin-2-
yl]amino]phenyl]benzamide 881674-34-6P, N-[4-[[4-(Pyridin-2-
yl)pyrimidin-2-yl]amino]phenyl]-4-trifluoromethoxybenzamide
881674-36-8P, 4-Chloro-N-[4-[[4-(pyridin-2-yl)pyrimidin-2-
yl]amino]phenyl]benzamide 881674-38-0P, 2-Methoxy-N-[4-[[4-
(pyridin-2-yl)pyrimidin-2-yl]amino]phenyl]benzamide 881674-40-4P
, 4-Methyl-N-[4-[[4-(pyridin-2-yl)pyrimidin-2-yl]amino]phenyl]benzamide
881674-44-8P, N-[4-[[4-(Pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]-
4-trifluoromethoxybenzamide 881674-49-3P, N-[4-[[4-(Pyridin-4-
yl)pyrimidin-2-yl]amino]phenyl]benzamide 881674-53-9P,
4-Methoxy-N-[4-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
881674-55-1P, 3,5-Dimethoxy-N-[4-[[4-(pyridin-2-yl)pyrimidin-2-
yl]amino]phenyl]benzamide 881674-57-3P, 3,5-Dimethoxy-N-[4-[[4-
(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 881675-55-4P
, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-[[4-(pyridin-2-yl)pyrimidin-2-
yl]amino]phenyl]benzamide 881675-87-2P, 3,4,5-Trimethoxy-N-[4-
[[4-(pyridin-4-yl)pyrimidin-2-yl]amino]phenyl]benzamide
881675-89-4P, 2-Methoxy-N-[4-[[4-(pyridin-4-yl)pyrimidin-2-
yl]amino]phenyl]benzamide 881675-95-2P, 4-Chloro-N-[4-[[4-
(pyridin-4-yl)pyrimidin-2-yl]amino]phenyl]benzamide 881676-03-5P
, 4-Bromo-N-[4-[[4-(pyridin-4-yl)pyrimidin-2-yl]amino]phenyl]benzamide
881676-05-7P, 2,3,4,5,6-Pentafluoro-N-[4-[[4-(pyridin-4-
yl)pyrimidin-2-yl]amino]phenyl]benzamide 881676-31-9P,
2-Methoxy-N-[4-methyl-3-[[4-(pyridin-4-yl)pyrimidin-2-
yl]amino]phenyl]benzamide 881676-36-4P, N-[4-Methyl-3-[[4-
(pyridin-4-yl)pyrimidin-2-yl]amino]phenyl]benzamide 881676-40-0P
, 4-Methyl-N-[4-methyl-3-[[4-(pyridin-4-yl)pyrimidin-2-
yl]amino]phenyl]benzamide 881677-01-6P, 4-[(4-Methylpiperazin-1-
yl)methyl]-N-[4-[[4-(pyridin-4-yl)pyrimidin-2-yl]amino]phenyl]benzamide
881677-31-2P, 4-Bromo-N-[4-methyl-3-[[4-(pyridin-2-yl)pyrimidin-2-
yl]amino]phenyl]benzamide 881677-35-6P, 4-Methyl-N-[4-methyl-3-
[[4-(pyridin-2-yl)pyrimidin-2-yl]amino]phenyl]benzamide
881677-39-0P, 4-Chloromethyl-N-[4-methyl-3-[[4-(pyridin-2-
yl)pyrimidin-2-yl]amino]phenyl]benzamide 881677-41-4P,


2-Methoxy-N-[4-methyl-3-[[4-(pyridin-2-yl)pyrimidin-2-yl]amino]phenyl]benzamide 881677-56-1P, 4-Chloromethyl-N-[3-[[4-(pyridin-4-yl)pyrimidin-2-yl]amino]phenyl]benzamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidine derivs. as phosphatase and kinase inhibitors for treating a variety of diseases)


RN 152459-76-2 CAPLUS

CN Benzamide, 4-chloro-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-86-4 CAPLUS

CN Benzamide, 2-methoxy-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-88-6 CAPLUS

CN Benzamide, 4-cyano-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-91-1 CAPLUS


CN Benzamide, 4-methyl-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 152459-92-2 CAPLUS


CN Benzamide, 4-chloro-N-[3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)

RN 152459-94-4 CAPLUS

CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
(CA INDEX NAME)


RN 152459-96-6 CAPLUS

CN Benzamide, 4-methyl-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-98-8 CAPLUS

CN Benzamide, 4-chloro-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-99-9 CAPLUS


CN Benzamide, 2-methoxy-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 404844-11-7 CAPLUS
 CN Benzamide, 4-(chloromethyl)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 475587-06-5 CAPLUS
 CN Benzamide, 4-(chloromethyl)-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 475587-08-7 CAPLUS
 CN Benzamide, 3,4,5-trimethoxy-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-09-8 CAPLUS
 CN Benzamide, 4-methoxy-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-12-3 CAPLUS
 CN Benzamide, 3,5-dimethoxy-N-[3-[(4-(3-pyridinyl)-2-

pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-13-4 CAPLUS

CN Benzamide, 3,4,5-trimethoxy-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-14-5 CAPLUS

CN Benzamide, 4-cyano-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-15-6 CAPLUS

CN Benzamide, 4-methoxy-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-18-9 CAPLUS


CN Benzamide, 3,5-dimethoxy-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-19-0 CAPLUS
 CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 475587-25-8 CAPLUS
 CN Benzamide, 3,4,5-trimethoxy-N-[4-methyl-3-[(4-(2-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-26-9 CAPLUS
 CN Benzamide, 4-cyano-N-[4-methyl-3-[(4-(2-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-27-0 CAPLUS
 CN Benzamide, 4-chloro-N-[4-methyl-3-[(4-(2-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-29-2 CAPLUS
 CN Benzamide, 4-cyano-N-[4-methyl-3-[(4-(4-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-31-6 CAPLUS
 CN Benzamide, 4-methoxy-N-[4-methyl-3-[(4-(4-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 475587-32-7 CAPLUS
 CN Benzamide, 4-chloro-N-[4-methyl-3-[(4-(4-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-34-9 CAPLUS
 CN Benzamide, 3,5-dimethoxy-N-[3-[(4-(4-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-38-3 CAPLUS

CN Benzamide, N-[4-methyl-3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 475587-40-7 CAPLUS

CN Benzamide, 4-methoxy-N-[3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-41-8 CAPLUS

CN Benzamide, 4-cyano-N-[3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-42-9 CAPLUS

CN Benzamide, 3,4,5-trimethoxy-N-[3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-43-0 CAPLUS


CN Benzamide, 3,5-dimethoxy-N-[4-methyl-3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-44-1 CAPLUS
 CN Benzamide, 3,4,5-trimethoxy-N-[4-methyl-3-[(4-(4-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-46-3 CAPLUS
 CN Benzamide, 4-methoxy-N-[4-methyl-3-[(4-(2-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-47-4 CAPLUS
 CN Benzamide, 3,5-dimethoxy-N-[4-methyl-3-[(4-(2-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-48-5 CAPLUS
 CN Benzamide, N-[3-[(4-(4-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-49-6 CAPLUS
 CN Benzamide, 4-chloro-N-[3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 475587-50-9 CAPLUS
 CN Benzamide, 4-methoxy-N-[3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 475587-57-6 CAPLUS
 CN Benzamide, 4-cyano-N-[3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 475587-58-7 CAPLUS
 CN Benzamide, 3,5-dimethoxy-N-[3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 475587-59-8 CAPLUS
 CN Benzamide, 4-bromo-N-[3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 475587-60-1 CAPLUS
 CN Benzamide, 4-methyl-N-[3-[(4-(2-pyridinyl)-2-pyrimidinyl)amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 475587-62-3 CAPLUS
 CN Benzamide, 3,5-dichloro-N-[3-[(4-(2-pyridinyl)-2-pyrimidinyl)amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 475587-63-4 CAPLUS
 CN Benzamide, N-[3-[(4-(2-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA
 INDEX NAME)




RN 475587-64-5 CAPLUS
 CN Benzamide, 4-(chloromethyl)-N-[3-[(4-(2-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-72-5 CAPLUS
 CN Benzamide, 2-methoxy-N-[3-[(4-(2-pyridinyl)-2-pyrimidinyl)amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 475587-73-6 CAPLUS
 CN Benzamide, N-[3-[(4-(4-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 475587-74-7 CAPLUS
 CN Benzamide, 4-methyl-N-[3-[(4-(4-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-70-0 CAPLUS
 CN Benzamide, 4-(chloromethyl)-N-[4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 881673-97-8 CAPLUS
 CN Benzamide, N-[4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 881674-08-4 CAPLUS
 CN Benzamide, 4-cyano-N-[4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 881674-14-2 CAPLUS
 CN Benzamide, 3,4,5-trimethoxy-N-[4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 881674-18-6 CAPLUS
 CN Benzamide, 2-methoxy-N-[4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 881674-19-7 CAPLUS
 CN Benzamide, 4-methyl-N-[4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 881674-23-3 CAPLUS
 CN Benzamide, 4-cyano-N-[4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 881674-24-4 CAPLUS
 CN Benzamide, 4-(chloromethyl)-N-[4-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 881674-26-6 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 881674-28-8 CAPLUS
 CN Benzamide, 4-chloro-N-[4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 881674-32-4 CAPLUS
 CN Benzamide, 3,4,5-trimethoxy-N-[4-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 881674-34-6 CAPLUS

CN Benzamide, N-[4-[(4-(2-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-(trifluoromethoxy)- (CA INDEX NAME)




RN 881674-36-8 CAPLUS

CN Benzamide, 4-chloro-N-[(4-(2-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 881674-38-0 CAPLUS

CN Benzamide, 2-methoxy-N-[(4-(2-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 881674-40-4 CAPLUS

CN Benzamide, 4-methyl-N-[(4-(2-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 881674-44-8 CAPLUS

CN Benzamide, N-[4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-(trifluoromethoxy)- (CA INDEX NAME)




RN 881674-49-3 CAPLUS

CN Benzamide, N-[4-[(4-(4-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 881674-53-9 CAPLUS

CN Benzamide, 4-methoxy-N-[4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 881674-55-1 CAPLUS

CN Benzamide, 3,5-dimethoxy-N-[4-[(4-(2-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 881674-57-3 CAPLUS


CN Benzamide, 3,5-dimethoxy-N-[4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 881675-55-4 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 881675-87-2 CAPLUS
 CN Benzamide, 3,4,5-trimethoxy-N-[4-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 881675-89-4 CAPLUS
 CN Benzamide, 2-methoxy-N-[4-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 881675-95-2 CAPLUS
 CN Benzamide, 4-chloro-N-[4-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 881676-03-5 CAPLUS
 CN Benzamide, 4-bromo-N-[4-[(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (CA INDEX NAME)




RN 881676-05-7 CAPLUS
 CN Benzamide, 2,3,4,5,6-pentafluoro-N-[4-[(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (CA INDEX NAME)




RN 881676-31-9 CAPLUS
 CN Benzamide, 2-methoxy-N-[4-methyl-3-[(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (CA INDEX NAME)




RN 881676-36-4 CAPLUS
 CN Benzamide, N-[4-methyl-3-[(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (CA INDEX NAME)




RN 881676-40-0 CAPLUS
 CN Benzamide, 4-methyl-N-[4-methyl-3-[(4-(4-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 881677-01-6 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-[(4-(4-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 881677-31-2 CAPLUS
 CN Benzamide, 4-bromo-N-[4-methyl-3-[(4-(2-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 881677-35-6 CAPLUS
 CN Benzamide, 4-methyl-N-[4-methyl-3-[(4-(2-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 881677-39-0 CAPLUS
 CN Benzamide, 4-(chloromethyl)-N-[4-methyl-3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 881677-41-4 CAPLUS
 CN Benzamide, 2-methoxy-N-[4-methyl-3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 881677-56-1 CAPLUS
 CN Benzamide, 4-(chloromethyl)-N-[3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



L10 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:235109 CAPLUS
 DN 144:312102

TI Preparation of (phenylamino)pyrimidine derivatives as inhibitors of BCR-ABL kinase for treatment of chronic myeloid leukemia
 IN Kompella, Amala Kishan; Adibhatla Kali Satya, Bhujanga Rao; Rachakonda, Sreenivas; Podili, Khadgapathi; Venkaiah Chowdary, Nannapaneni
 PA Natco Pharma Limited, India
 SO PCT Int. Appl., 85 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006027795	A1	20060316	WO 2005-IN243	20050719
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
	IN 2004CH00908	A	20061103	IN 2004-CH908	20040909
	AU 2005281299	A1	20060316	AU 2005-281299	20050719
	CA 2591321	A1	20060316	CA 2005-2591321	20050719
	EP 1786799	A1	20070523	EP 2005-779775	20050719
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	NO 2007001521	A	20070611	NO 2007-1521	20070322
	IN 2007CN01426	A	20070831	IN 2007-CN1426	20070409

PRAI IN 2004-CH908 A 20040909
 WO 2005-IN243 W 20050719

OS CASREACT 144:312102; MARPAT 144:312102

AB The present invention relates to preparation of novel (phenylamino)pyrimidine derivs. I [wherein X = CH or N; n = 1 or 2; R = H or Me; R' = CF₃] or pharmaceutically acceptable salts thereof as inhibitors of BCR-ABL kinase for the treatment of chronic myeloid leukemia (CML). For example, the compound II was prepared in a multi-step synthesis in good yield.

Pharmaceutical composition containing the novel (phenylamino)pyrimidine derivs. and

processes for their prepn were also presented. Since the IC₅₀ values of these mols. are in the range of 0.1 to 10.0 nm, these novel compds. are potentially useful for the treatment of CML.


IT 879507-24-1P 879507-25-2P 879507-26-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of (phenylamino)pyrimidine derivs. as inhibitors of BCR-ABL kinase for treatment of chronic myeloid leukemia)

RN 879507-24-1 CAPLUS


CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)



RN 879507-25-2 CAPLUS
 CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-3,5-bis(trifluoromethyl)- (CA INDEX NAME)



RN 879507-26-3 CAPLUS
 CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 11 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:176834 CAPLUS

DN 144:370108

TI Preparation and application of phenylamino pyrimidine derivatives
 IN Chen, Guoqing

PA Chen Guoqing, Peop. Rep. China

SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 41 pp.

CODEN: CNXXEV

DT Patent

LA Chinese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CN 1560050	A	20050105	CN 2004-10014093	20040218
PRAI CN 2004-10014093		20040218		
OS MARPAT 144:370108				

AB The invention relates to a phenylamino pyrimidine derivative, its preparing process, medicines adopting it as active component, a method of curing the diseases relative to tyrosine kinase, especially to Bcr-Abl, like cancers, etc, and the application of its acting as medicine and making tyrosine kinase inhibition medicines to relieve the effect of tyrosine kinase to endotherms like human beings.


IT 791609-55-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and application of phenylamino pyrimidine derivs.)

RN 791609-55-7 CAPLUS

CN Benzamide, 4-hydroxy-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



IT 791609-56-8P 791609-58-0P 791609-62-6P

791609-63-7P 791609-65-9P 791609-67-1P

791609-68-2P 791609-69-3P 791609-71-7P

791609-74-0P 791609-75-1P 791609-76-2P

791609-79-5P 791609-81-9P 791609-82-0P

791609-84-2P 791609-85-3P 882166-62-3P


882166-63-4P 882166-64-5P 882166-67-8P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and application of phenylamino pyrimidine derivs.)


RN 791609-56-8 CAPLUS

CN Benzamide, 4-(2-aminoethoxy)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 791609-58-0 CAPLUS

CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(1-methyl-3-pyrrolidinyl)amino]- (CA INDEX NAME)




RN 791609-62-6 CAPLUS

CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(1-methyl-2-pyrrolidinyl)methoxy]- (CA INDEX NAME)




RN 791609-63-7 CAPLUS

CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-(3-pyrrolidinylamino)- (CA INDEX NAME)




RN 791609-65-9 CAPLUS

CN Benzamide, 4-(aminofluoromethyl)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 791609-67-1 CAPLUS

CN Benzamide, 4-(aminodifluoromethyl)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)



RN 791609-68-2 CAPLUS


CN Benzamide, 4-[methyl(1-methyl-3-pyrrolidinyl)amino]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 791609-69-3 CAPLUS

CN Benzamide, 4-[fluoro[(1-methyl-3-pyrrolidinyl)amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 791609-71-7 CAPLUS

CN Benzamide, 4-[[[2-(dimethylamino)ethyl]amino]fluoromethyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 791609-74-0 CAPLUS


CN Benzamide, 4-[[[2-(dimethylamino)ethyl]amino]difluoromethyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 791609-75-1 CAPLUS

CN Benzamide, 4-[[[2-(dimethylamino)ethyl]amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 791609-76-2 CAPLUS

CN Benzamide, 4-[fluoro(3-pyrrolidinylamino)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 791609-79-5 CAPLUS

CN Benzamide, 4-[difluoro[methyl(1-methyl-3-pyrrolidinyl)amino]methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 791609-81-9 CAPLUS

CN Benzamide, 4-[difluoro(3-pyrrolidinylamino)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 791609-82-0 CAPLUS
CN Benzamide, 4-[[methyl(1-methyl-3-pyrrolidinyl)amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 791609-84-2 CAPLUS

CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(1-methyl-3-pyrrolidinyl)amino]methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 791609-85-3 CAPLUS
CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(3-pyrrolidinylamino)methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 882166-62-3 CAPLUS


CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-(methyl-3-pyrrolidinylamino)- (CA INDEX NAME)



RN 882166-63-4 CAPLUS

CN Benzamide, 4-[fluoro(methyl-3-pyrrolidinylamino)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 882166-64-5 CAPLUS

CN Benzamide, 4-[difluoro(methyl-3-pyrrolidinylamino)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 882166-67-8 CAPLUS

CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(methyl-3-pyrrolidinylamino)methyl]- (CA INDEX NAME)

10/528, 913


PAGE 1-A



PAGE 2-A



L10 ANSWER 12 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:1068885 CAPLUS
 DN 143:338914
 TI Metabolism and disposition of imatinib mesylate in healthy volunteers
 AU Gschwind, Hans-Peter; Pfaar, Ulrike; Waldmeier, Felix; Zollinger, Markus;
 Sayer, Claudia; Zbinden, Peter; Hayes, Michael; Pokorny, Rolf; Seiberling,
 Michael; Ben-Am, Monique; Peng, Bin; Gross, Gerhard
 CS Exploratory Development/Drug Metabolism & Pharmacokinetics, Novartis
 Pharma AG, Basel, Switz.
 SO Drug Metabolism and Disposition (2005), 33(10), 1503-1512
 CODEN: DMDSAI; ISSN: 0090-9556
 PB American Society for Pharmacology and Experimental Therapeutics
 DT Journal
 LA English
 AB Imatinib mesylate (GLEEVEC, GLIVEC, formerly STI571) has demonstrated unprecedented efficacy as first-line therapy for treatment for all phases of chronic myelogenous leukemia and metastatic and unresectable malignant gastrointestinal stromal tumors. Disposition and biotransformation of imatinib were studied in four male healthy volunteers after a single oral dose of 239 mg of 14C-labeled imatinib mesylate. Biol. fluids were analyzed for total radioactivity, imatinib, and its main metabolite CGP74588. Metabolite patterns were determined by radio-high-performance liquid chromatog. with off-line microplate solid scintillation counting and characterized by liquid chromatog.-mass spectrometry. Imatinib treatment was well tolerated without serious adverse events. Absorption was rapid (tmax 1-2 h) and complete with imatinib as the major radioactive compound in plasma. Maximum plasma concns. were 0.921 ± 0.095 $\mu\text{g}/\text{mL}$ (mean \pm S.D., n = 4) for imatinib and 0.115 ± 0.026 $\mu\text{g}/\text{mL}$ for the pharmacol. active N-desmethyl metabolite (CGP74588). Mean plasma terminal elimination half-lives were 13.5 ± 0.9 h for imatinib, 20.6 ± 1.7 h for CGP74588, and 57.3 ± 12.5 h for 14C radioactivity. Imatinib was predominantly cleared through oxidative metabolism. Approx. 65 and 9% of total systemic exposure [AUC₀₋₂₄ h (area under the concentration time curve) of radioactivity] corresponded to imatinib and CGP74588, resp. The remaining proportion corresponded mainly to oxidized derivs. of imatinib and CGP74588. Imatinib and its metabolites were excreted predominantly via the biliary-fecal route. Excretion of radioactivity was slow with a mean radiocarbon recovery of 80% within 7 days (67% in feces, 13% in urine). Approx. 28 and 13% of the dose in the excreta corresponded to imatinib and CGP74588, resp.
 IT 865487-51-0
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (metabolism and disposition of imatinib mesylate in healthy volunteers)
 RN 865487-51-0 CAPLUS
 CN Benzoic acid, 4-[[[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]amino]carbonyl]- (CA INDEX NAME)



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 13 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:982360 CAPLUS
 DN 143:281777

TI Photosensitizer-kinase modulator conjugates for the treatment of protein kinase-dependent diseases

IN Bourre, Ludovic

PA Fr.

SO Fr. Demande, 26 pp.

CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR 2867189	A1	20050909	FR 2004-2408	20040308
PRAI FR 2004-2408		20040308		

AB The invention discloses compds. modulating protein kinase activity, as well as drugs and pharmaceutical compns. for the treatment of diseases dependent on protein kinase activity. The compds. are conjugates of ≥ 1 photoactive mols. and ≥ 1 protein kinase modulators. The compds. are useful for photochemotherapy. Compound preparation is included.

IT 863994-25-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(photosensitizer-kinase modulator conjugates for treatment of protein kinase-dependent diseases)


RN 863994-25-6 CAPLUS

CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[7,12,17-tris(4-methylphenyl)-21,22,23,24-tetraazapentacyclo[16.2.1.13,6.1.8,11.113,16]tetracosa-1,3(24),4,6,8,10,12,14,16(22),17,19-undecaen-2-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RE.CNT 7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 14 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:638614 CAPLUS
 DN 143:149136
 TI Protection of tissues and cells from cytotoxic effects of ionizing radiation by ABL inhibitors
 IN Reddy, E. Premkumar; Reddy, M. V. Ramana; Cosenza, Stephen C.; Gumireddy, Kiranmai
 PA Temple University of the Commonwealth System of Higher Education, USA
 SO PCT Int. Appl., 151 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005065074	A2	20050721	WO 2004-US28654	20040902
	WO 2005065074	A3	20060223		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2003-501783P P 20030909

OS MARPAT 143:149136


AB Pre-treatment with ABL protein kinase inhibitors protects normal cells from the toxic side effects of ionizing radiation. Administration of one or more radioprotectant to a patient prior to anticancer radiotherapy reduces the cytotoxic side effects of the radiation on normal cells. The radioprotective effect allows for safely increasing the dosage of anticancer radiation. Amelioration of toxicity following inadvertent radiation exposure may also be mitigated.

IT 152459-77-3 152459-82-0 152459-86-4
 152459-87-5 152459-88-6 152459-91-1
 152459-94-4 152459-96-6 152459-98-8
 152459-99-9

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (ABL protein kinase inhibitors as radioprotectants)


RN 152459-77-3 CAPLUS

CN Benzamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-82-0 CAPLUS


CN Benzoic acid, 2-[[[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 152459-86-4 CAPLUS
 CN Benzamide, 2-methoxy-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 152459-87-5 CAPLUS
 CN Benzamide, 4-fluoro-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 152459-88-6 CAPLUS
 CN Benzamide, 4-cyano-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 152459-91-1 CAPLUS
 CN Benzamide, 4-methyl-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 152459-94-4 CAPLUS
 CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (CA INDEX NAME)




RN 152459-96-6 CAPLUS
 CN Benzamide, 4-methyl-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 152459-98-8 CAPLUS
 CN Benzamide, 4-chloro-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 152459-99-9 CAPLUS
 CN Benzamide, 2-methoxy-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 15 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:614536 CAPLUS
 DN 143:115392
 TI Preparation of conjugated small molecules for diagnostic and therapeutic use
 IN Grotzfeld, Robert M.; Milanov, Zdravko V.; Patel, Hitesh K.; Lai, Andiliy G.; Mehta, Shamal A.; Lockhart, David J.
 PA Ambit Biosciences Corp., USA
 SO U.S. Pat. Appl. Publ., 63 pp.
 CODEN: USXXCO


DT Patent
 LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005153371	A1	20050714	US 2005-31638	20050107
	AU 2005204428	A1	20050728	AU 2005-204428	20050107
	CA 2551495	A1	20050728	CA 2005-2551495	20050107
	WO 2005067644	A2	20050728	WO 2005-US456	20050107
	WO 2005067644	A3	20051013		
				W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
	EP 1711825	A2	20061018	EP 2005-705221	20050107
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
PRAI	JP 2007521338	T	20070802	JP 2006-549423	20050107
	US 2004-535173P	P	20040107		
	US 2004-557941P	P	20040330		
	WO 2005-US456	W	20050107		
AB	Provided herein are linker compds. and conjugates that include the linker compds. In one embodiment, the linker compds. comprise 2 or 3 residues of 6-aminohexanoic acid and optionally 7-10 residues of polyethyleneglycol (PEG). The linker compds. are useful in forming conjugates with one or more components useful in biopharmaceutical or bioanal. applications. In particular, the biopharmaceutically useful compds. are kinase inhibitors. The conjugates described herein have utility in a variety of diagnostic, separation, and therapeutic applications. Thus, I was prepared from SB 202190, PEG-azide and the biotin-linker compound				
IT	857892-09-2P RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of conjugated biotins for diagnostic and therapeutic use)				
RN	857892-09-2	CAPLUS			
CN	1,4-Benzenedicarboxamide, N-[49-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-31,38,45-trioxo-3,6,9,12,15,18,21,24,27-nonaoxa-30,37,44-triazanonetetracont-1-yl]-N'-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 1-C



10/528,913

PAGE 1-D



L10 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:612254 CAPLUS
 DN 143:133396
 TI Preparation of heterocyclyl moiety-containing amides as BCR-ABL tyrosine kinase inhibitors
 IN Asaki, Tetsuo; Sugiyama, Yukiteru; Segawa, Jun
 PA Nippon Shinyaku Co., Ltd., Japan
 SO PCT Int. Appl., 168 pp.
 CODEN: PIXXD2

DT Patent
 LA Japanese
 FAN CNT 1

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

PI	WO 2005063709	A1	20050714	WO 2004-JP19553	20041227
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, II, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004309248	A1	20050714	AU 2004-309248	20041227
	CA 2551529	A1	20050714	CA 2004-2551529	20041227
	EP 1702917	A1	20060920	EP 2004-807908	20041227
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	CN 1898208	A	20070117	CN 2004-80039048	20041227
	BR 2004018074	A	20070417	BR 2004-18074	20041227
	MX 2006PA07237	A	20060818	MX 2006-PA7237	20060622
	IN 2006CN02337	A	20070706	IN 2006-CN2337	20060626

PRAI JP 2003-431398 A 20031225
 WO 2004-JP19553 W 20041227


OS MARPAT 143:133396

AB The title compds. I (R1 represents CH2R11 (R11 represents a nitrogenous saturated heterocyclic group), etc.; R2 represents alkyl, halogeno, haloalkyl, etc.; R3 represents hydrogen, halogeno, alkoxy; Het1 represents Q1, etc.; and Het2 represents pyrimidinyl, etc.) are prepared Thus 3-difluoromethyl-4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl]benzamide was prepared from 4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]aniline and 3-difluoromethyl-4-(4-methylpiperazin-1-ylmethyl)benzoyl chloride HCl salt. In an assay (for cell proliferation inhibiting activity) using K562 cells, compds. of this invention showed IC50 values of < 0.00001 μ M to 0.001 μ M. Formulations are given.

IT 859212-54-7P 859212-55-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of heterocyclyl moiety-containing amides as BCR-ABL tyrosine kinase inhibitors)


RN 859212-54-7 CAPLUS

CN Benzamide, 4-[(1-methyl-4-piperidinyl)oxy]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)



RN 859212-55-8 CAPLUS

CN Benzamide, 4-[(1-methyl-4-piperidinylidene)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




IT 641615-11-4P 641615-12-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclyl moiety-containing amides as BCR-ABL tyrosine kinase inhibitors)


RN 641615-11-4 CAPLUS

CN Benzamide, 3-bromo-4-[(dimethylamino)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-12-5 CAPLUS

CN Benzamide, 3-bromo-4-[(diethylamino)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD

L10 ANSWER 17 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:366660 CAPLUS
 DN 143:126017
 TI Engineering 3-alkyltriazenes to block bcr-abl kinase: a novel strategy for the therapy of advanced bcr-abl expressing leukemias
 AU Katsoulas, Athanasia; Rachid, Zakaria; Brahimi, Fouad; McNamee, James; Jean-Claude, Bertrand J.
 CS Cancer Drug Research Laboratory, Department of Medicine, Division of Medical Oncology, McGill University Health Center/Royal Victoria Hospital, Montreal, QC, H3A 1A1, Can.
 SO Leukemia Research (2005), 29(6), 693-700
 CODEN: LEREDD; ISSN: 0145-2126
 PB Elsevier B.V.
 DT Journal
 LA English
 AB Recently, within the framework of a new strategy termed "combi-targeting," we designed ZRCM5 to contain a 2-phenylaminopyrimidopyridine moiety targeted to bcr-abl kinase and a triazene tail capable of generating a methyldiazonium species upon hydrolysis. The ability of ZRCM5 to block tyrosine kinase activity was tested in a short 10 min exposure ELISA involving isolated bcr-abl kinase and Western blotting assays. The results showed that: (a) ZRCM5 was hydrolyzed with a half-life of 27 min in cell culture media, (b) it blocked bcr-abl autophosphorylation in promyeloblastic leukemia K562 cells in a dose-dependent manner ($IC_{50} = 14.01 \mu M$) and (c) it induced dose-dependent levels of DNA strand breaks. In contrast, temozolomide (TEM), a clin. DNA damaging triazene capable of generating, like ZRCM5, a methyldiazonium species, could neither block bcr-abl tyrosine kinase activity in isolated enzyme nor in whole cell autophosphorylation assays. In cells expressing varied levels of bcr-abl, ZRCM5 was consistently more potent than TEM. The significant potency of ZRCM5 against the leukemia cells was attributed to its ability to simultaneously to block bcr-abl and related DNA repair activity while inducing significant DNA lesions in bcr-abl expressing leukemia cells. Further studies are ongoing to increase the affinity of ZRCM5 with the purpose of further enhancing its potency in bcr-abl expressing cells.
 IT 623901-04-2
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (ZRCM5 blocked bcr-abl kinase autophosphorylation, induced DNA strand breaks by dose dependent manner and also induced apoptosis, cytotoxicity in advanced bcr-abl expressing leukemia K562 cells)
 RN 623901-04-2 CAPLUS
 CN Benzamide, 4-[3-(hydroxymethyl)-3-methyl-1-triazenyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 18 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:1124644 CAPLUS

DN 142:74589

TI 2-Aminopyrimidine derivatives as Raf kinase inhibitors, process for their preparation, and their use, e.g., in the treatment of proliferative diseases such as cancer

IN Batt, David Bryant; Ramsey, Timothy Michael; Sabio, Michael Lloyd

PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SO PCT Int. Appl., 69 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004110452	A1	20041223	WO 2004-EP6317	20040611
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004246800	A1	20041223	AU 2004-246800	20040611
	CA 2529090	A1	20041223	CA 2004-2529090	20040611
	EP 1635835	A1	20060322	EP 2004-739809	20040611
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	CN 1805748	A	20060719	CN 2004-80016328	20040611
	BR 2004011365	A	20060725	BR 2004-11365	20040611
	JP 2006527230	T	20061130	JP 2006-515898	20040611
	US 2006293340	A1	20061228	US 2004-560352	20040611
	MX 2005PA13349	A	20060309	MX 2005-PA13349	20051208
	IN 2005CN03360	A	20070914	IN 2005-CN3360	20051212
PRAI	US 2003-478709P	P	20030613		
	WO 2004-EP6317	W	20040611		

OS MARPAT 142:74589

AB The application discloses compds. that inhibit Raf kinase, having formula I [wherein R1 is an (un)substituted Ph or heteroaryl radical; and R2 is an (un)substituted Ph radical; or an N-oxide or pharmaceutically acceptable salt thereof]. Also disclosed are methods of treating diseases characterized by excessive signaling through the MAP kinase pathway by administering a RAF kinase-inhibiting amount of a compound I. In particular, I are useful for the treatment of proliferative diseases such as cancer. Over 30 compds. I were prepared. For instance, amidation of 4-methyl-N3-[4-(pyrazin-2-yl)pyrimidin-2-yl]benzene-1,3-diamine with 3-CF3C6H4CO2H using BOP reagent and DIEA in DMF gave invention compound II. The prepared compds. I inhibited human Raf proteins as follows (IC50): wild-type C-Raf 0.01-0.7 μM; wild-type B-Raf 0.04-1.5 μM; and mutant B-Raf (V599E) 0.006-1.6 μM.


IT 812699-95-9P, N-[3-[(4-(6-Chloropyridin-3-yl)pyrimidin-2-yl)amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of aminopyrimidine derivs. as Raf kinase

RN inhibitors for treatment of proliferative diseases such as cancer)
RN 812699-95-9 CAPLUS
CN Benzamide, N-[3-[[4-(6-chloro-3-pyridinyl)-2-pyrimidinyl]amino]-4-methylphenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




IT 812699-92-6P, N-[4-Methyl-3-[[4-[6-[[3-(morpholin-4-yl)propyl]amino]pyridin-3-yl]pyrimidin-2-yl]amino]phenyl]-3-(trifluoromethyl)benzamide 812699-93-7P, N-[4-Methyl-3-[[4-[6-(pyridin-4-ylamino)pyridin-3-yl]pyrimidin-2-yl]amino]phenyl]-3-(trifluoromethyl)benzamide 812699-94-8P, 3-(Difluoromethoxy)-N-[3-[[4-[6-[(2-hydroxyethyl)amino]pyridin-3-yl]pyrimidin-2-yl]amino]-4-methylphenyl]benzamide 812699-96-0P, N-[3-[[4-[6-(Dimethylamino)pyridin-3-yl]pyrimidin-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide 812699-97-1P, N-[3-[[4-[6-(2-Methoxyethoxy)pyridin-3-yl]pyrimidin-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide 812699-99-3P, N-[4-Methyl-3-[[4-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]pyrimidin-2-yl]amino]phenyl]-3-(trifluoromethyl)benzamide 812700-01-9P, N-[4-Methyl-3-[[4-[6-(methylamino)pyridin-3-yl]pyrimidin-2-yl]amino]phenyl]-3-(trifluoromethyl)benzamide 812700-03-1P, N-[3-[[4-[6-(Cyclopropylamino)pyridin-3-yl]pyrimidin-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide 812700-05-3P, N-[3-[[4-[6-(Cyclopentylamino)pyridin-3-yl]pyrimidin-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide 812700-07-5P, N-[4-Methyl-3-[[4-[6-(thiomorpholin-4-yl)pyridin-3-yl]pyrimidin-2-yl]amino]phenyl]-3-(trifluoromethyl)benzamide 812700-08-6P, N-[4-Methyl-3-[[4-[6-(morpholin-4-yl)pyridin-3-yl]pyrimidin-2-yl]amino]phenyl]-3-(trifluoromethyl)benzamide 812700-09-7P, N-[3-[[4-(4-Hydroxy-3,4,5,6-tetrahydro[1,2']bipyridinyl-5'-yl)pyrimidin-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide 812700-10-0P, N-[3-[[4-[6-[[3-(Diethylamino)propyl]amino]pyridin-3-yl]pyrimidin-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide 812700-11-1P, N-[4-Methyl-3-[[4-[6-[(pyridin-4-ylmethyl)amino]pyridin-3-yl]pyrimidin-2-yl]amino]phenyl]-3-(trifluoromethyl)benzamide 812700-12-2P, N-[3-[[4-[6-[(2-Methoxyethyl)amino]pyridin-3-yl]pyrimidin-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide 812700-13-3P, N-[3-[[4-[6-[(2-Hydroxypropyl)sulfanyl]pyridin-3-yl]pyrimidin-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide 812700-14-4P, N-[4-Methyl-3-[[4-[6-(pyridin-3-yloxy)pyridin-3-yl]pyrimidin-2-yl]amino]phenyl]-3-(trifluoromethyl)benzamide 812700-15-5P, N-[4-Methyl-3-[[4-[6-[(1-methylpiperidin-4-yl)oxy]pyridin-3-yl]pyrimidin-2-yl]amino]phenyl]-3-(trifluoromethyl)benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aminopyrimidine derivs. as Raf kinase inhibitors for treatment of proliferative diseases such as cancer)
RN 812699-92-6 CAPLUS
CN Benzamide, N-[4-methyl-3-[[4-[6-[[3-(4-morpholinyl)propyl]amino]-3-pyridinyl]-2-pyrimidinyl]amino]-3-(trifluoromethyl)- (CA INDEX NAME)

NAME)




RN 812699-93-7 CAPLUS

CN Benzamide, N-[4-methyl-3-[(4-[6-(4-pyridinylamino)-3-pyridinyl]-2-pyrimidinyl]amino]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 812699-94-8 CAPLUS


CN Benzamide, 3-(difluoromethoxy)-N-[3-[(4-[6-[(2-hydroxyethyl)amino]-3-pyridinyl]-2-pyrimidinyl]amino]-4-methylphenyl]- (CA INDEX NAME)




RN 812699-96-0 CAPLUS

CN Benzamide, N-[3-[(4-[6-(dimethylamino)-3-pyridinyl]-2-pyrimidinyl]amino]-4-methylphenyl]-3-(trifluoromethyl)- (CA INDEX NAME)







RN 812699-99-3 CAPLUS
 CN Benzamide, N-[4-methyl-3-[(4-[(4-methyl-1-piperazinyl)-3-pyridinyl]-2-pyrimidinyl]amino]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 812700-01-9 CAPLUS
 CN Benzamide, N-[4-methyl-3-[(4-[(4-methylamino)-3-pyridinyl]-2-pyrimidinyl]amino]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)



RN 812700-03-1 CAPLUS
 CN Benzamide, N-[3-[(4-[(4-methylamino)-3-pyridinyl]-2-pyrimidinyl]amino]-4-methylphenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 812700-05-3 CAPLUS
 CN Benzamide, N-[3-[(4-[(4-methylamino)-3-pyridinyl]-2-pyrimidinyl]amino]-4-methylphenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 812700-07-5 CAPLUS

CN Benzamide, N-[4-methyl-3-[(4-[6-(4-thiomorpholinyl)-3-pyridinyl]-2-pyrimidinyl)amino]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 812700-08-6 CAPLUS

CN Benzamide, N-[4-methyl-3-[(4-[6-(4-morpholinyl)-3-pyridinyl]-2-pyrimidinyl)amino]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 812700-09-7 CAPLUS

CN Benzamide, N-[3-[(4-[6-(4-hydroxy-1-piperidinyl)-3-pyridinyl]-2-pyrimidinyl)amino]-4-methylphenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 812700-10-0 CAPLUS


CN Benzamide, N-[3-[(4-[6-[[3-(diethylamino)propyl]amino]-3-pyridinyl]-2-pyrimidinyl)amino]-4-methylphenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 812700-11-1 CAPLUS
 CN Benzamide, N-[4-methyl-3-[(4-[(4-pyridinylmethyl)amino]-3-pyridinyl]-2-pyrimidinyl]amino]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 812700-12-2 CAPLUS
 CN Benzamide, N-[3-[(4-[(2-methoxyethyl)amino]-3-pyridinyl]-2-pyrimidinyl]amino]-4-methylphenyl]-3-(trifluoromethyl)- (CA INDEX NAME)



RN 812700-13-3 CAPLUS
 CN Benzamide, N-[3-[(4-[(2-hydroxypropyl)thio]-3-pyridinyl]-2-pyrimidinyl]amino]-4-methylphenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 812700-14-4 CAPLUS
 CN Benzamide, N-[4-methyl-3-[(4-[(3-pyridinyloxy)-3-pyridinyl]-2-pyrimidinyl]amino]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)



RN 812700-15-5 CAPLUS

CN Benzamide, N-[4-methyl-3-[[4-[6-[(1-methyl-4-piperidinyl)oxy]-3-pyridinyl]-2-pyrimidinyl]amino]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




IT 812700-23-5, N-[3-[[4-(6-Chloropyridin-3-yl)pyrimidin-2-yl]amino]-4-methylphenyl]-3-(difluoromethoxy)benzamide

RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of aminopyrimidine derivs. as Raf kinase inhibitors for treatment of proliferative diseases such as cancer)

RN 812700-23-5 CAPLUS

CN Benzamide, N-[3-[[4-(6-chloro-3-pyridinyl)-2-pyrimidinyl]amino]-4-methylphenyl]-3-(difluoromethoxy)- (CA INDEX NAME)

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 19 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:1080884 CAPLUS
 DN 142:56339

TI Process for the preparation of the anti-cancer drug imatinib and its analogs via aminolysis of a (chloromethyl)benzamide intermediate
 IN Kompella, Amala; Bhujanga Rao, Adibhatla Kali Sathya; Venkaiah Chowdary, Nannapaneni; Srinivas, Rachakonda
 PA Natco Pharma Limited, India
 SO PCT Int. Appl., 65 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004108699	A1	20041216	WO 2003-IN211	20030606
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003242988	A1	20050104	AU 2003-242988	20030606

PRAI WO 2003-IN211 A 20030606

OS CASREACT 142:56339

AB The invention discloses a process for the manufacture of imatinib [I; X = 4-methylpiperazin-1-yl] and three of its new analogs I [X = morpholin-4-yl, piperidin-1-yl, and imidazol-1-yl] through aminolysis of the intermediate I [X = Cl]. The mesylate (methanesulfonate) salt of imatinib is a popular life-saving drug, used to treat chronic myelogenous leukemia (CML). The other compds. are claimed as protein tyrosine kinase inhibitors (no data). The new process involves fewer steps (7) than the 9 steps in the known process disclosed in EP 0564409 and US 55211584, making the new process simple and cost effective. Yields are fairly high in all steps (65-90%), as compared to 20-50% realized by the prior art process. Reaction times are fairly low (8-10 h) in all steps, as compared to the time (12-25 h) for most of the stages in the prior art process. Obnoxious, foul smelling, and difficult-to-handle reagents are avoided, making the process safe and environmentally safe for com. application. Column chromatog., which is not practical on com. scale, is avoided at all stages. Consequently the process is simple and economical. Thus, 2-amino-4-nitrotoluene in BuOH was treated with HNO3 and then with aqueous cyanamide, and the mixture was heated at 90-95° for 12 h, to give 61% yield of 2-methyl-5-nitrophenylguanidine nitrate (II) on a 22-kg scale, with simple recovery of pure, unreacted 2-amino-4-nitrotoluene from the mother liquors, also on a multi-kg scale. Cyclization of II with 3-(dimethylamino)-1-(3-pyridyl)-2-propen-1-one in refluxing BuOH in the presence of NaOH for 10 h gave intermediate III quant., with III being isolated in 88% yield on a 21-kg scale. This was followed by reduction of the nitro group of III, using SnCl2 in concentrated HCl, to give the corresponding amine in 61.5% yield, on a 10-kg scale. The amine was amidated with 4-(ClCH2)C6H4COCl (preparation given) using Et3N in CHCl3, giving the (chloromethyl)benzamide intermediate I [X = Cl] in 70% yield on a 13.9-kg scale. This compound reacted with N-methylpiperazine in DMF over 4 h at 20-40°, giving imatinib free base after extraction into CHCl3, carbon treatment, evaporation, and trituration with EtOAc. Imatinib was obtained in


61% yield, 99.8% purity by HPLC, and on a 9.8-kg scale. The other three products I were obtained almost identically, using different amines in the final step.

IT 404844-11-7P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process intermediate; manufacture of imatinib and analogs via aminolysis of (chloromethyl)benzamide intermediate)


RN 404844-11-7 CAPLUS

CN Benzamide, 4-(chloromethyl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 20 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:1067788 CAPLUS
 DN 142:204407
 TI Acid-Base Profiling of Imatinib (Gleevec) and Its Fragments
 AU Szakacs, Zoltan; Beni, Szabolcs; Varga, Zoltan; Oerfi, Laszlo; Keri,
 Gyoergy; Noszal, Bela
 CS Department of Inorganic and Analytical Chemistry, Lorand Eotvos
 University, Budapest, H-1117, Hung.
 SO Journal of Medicinal Chemistry (2005), 48(1), 249-255
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 142:204407
 AB The site-specific basicities of imatinib (I) (Gleevec, a new signal transduction inhibitor drug of chronic myeloid leukemia) and two of its fragment compds. were quantitated in terms of protonation macroconstants, microconstants, and group consts. by NMR-pH and pH-potentiometric titrns. Sequential protonation of imatinib follows the N34, N11, N31, N13 order, in which N11 and N31 show commensurable basicity, but negligible intramol. interaction. Fragment compds. include two "halves" of imatinib, and their moiety-specific basicities confirm the NMR-based protonation sequence of the parent compound NMR-pH profiles, macro- and/or microscopic protonation schemes, and species-specific distribution diagrams are presented. On the basis of these data, imatinib is shown to be predominantly neutral, monocationic, and tricationic at intestinal, blood, and gastric pH, resp. The mol. hypotheses on imatinib binding to the Bcr-Abl oncogene fusion protein are interpreted at the site-specific level in view of the moiety basicities of imatinib.
 IT 404844-11-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (acid-base profiling of imatinib (Gleevec) and its fragments)
 RN 404844-11-7 CAPLUS
 CN Benzamide, 4-(chloromethyl)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 21 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:1060780 CAPLUS
 DN 142:38275
 TI Preparation of N-phenyl-2-pyrimidine-amine derivatives as anticancer agents and process for the preparation thereof
 IN Kim, Dong-Yeon; Kim, Jae-Gun; Cho, Dae-Jin; Lee, Gong-Yeal; Kim, Hong-Youb; Woo, Seok-Hun; Kim, Yong-Seok; Bae, Woo-Chul; Lee, Sun-Ahe; Han, Byoung-Cheol
 PA Il Yang Pharm. Co., Ltd., S. Korea
 SO U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 446,446, abandoned.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004248918	A1	20041209	US 2004-806834	20040322
PRAI	KR 2003-28669	A	20030506		
	US 2003-446446	B2	20030528		

OS MARPAT 142:38275

AB The title compds. (I) [R1 = 3- or 4-pyridyl; R2, R3 = H, lower alkyl; R6, R7 = Q; wherein X = O, NH; n= 0, 1; R9 = C5-10 9 aliphatic radical, 5- to 7-membered (un)saturated monocyclic radical, or bi- or tricyclic radical optionally combined with benzene ring, each of which has 1 to 3 hetero atoms selected from a group consisting of N, O, and S, piperazinyl or homopiperazinyl each of which is substituted by lower alkyl; R4, R5, R7, R8 = H or one or two thereof each represent halogen, lower alkyl, or lower alkoxy; when R6 is Q, or one or two of R4, R5, R6, and R8 each represent halogen, lower alkyl, or lower alkoxy; when R7 is Q, provided that R6 or R7 represents Q wherein n = 0 and R9 = 4-methylpiperazine, then one or more of R4, R5, R7, and R8, or one or more of R4, R5, R6, and R8 are halogen] or salts thereof are prepared. These compds. show a superior effect on lung cancer, gastric cancer, colon cancer, pancreatic cancer, hepatoma, prostatic cancer, breast cancer, chronic or acute leukemia, hematol. malignancy, encephalophyma, bladder cancer, rectal cancer, or cervical cancer of warm-blooded animals. The present invention also relates to a process for preparing the compound I, and to a pharmaceutical composition for

the

treatment of the above various diseases, which comprises an effective amount of the compound as an active ingredient together with pharmaceutically acceptable inert carriers. Thus, 3-dimethylamino-1-(3-pyridyl)-2-propen-1-one was cyclocondensed with 2-methyl-5-nitrophenylguanidine nitrate in the presence of sodium hydroxide in isopropanol under reflux for 18 h to give N-(2-methyl-5-nitrophenyl)-4-(3-pyridyl)-2-pyrimidineamine which was reduced by stannous chloride dihydrate in EtOAc/ethanol under reflux for 4 h to give N-(5-amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidineamine (II). II underwent amidation with 4-chloromethylbenzoyl chloride in Et₃N in THF under reflux for 4 h to give N-[5-(4-chloromethylbenzoylamino)-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidineamine which was stirred with pyridine for 30 min and then refluxed with N-methylhomopiperazine for 12 h to give 4-(4-methylhomopiperazin-1-ylmethyl)-N-[4-methyl-3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide (III). III methanesulfonate and 4-[(4-methylpiperazin-1-ylamino)methyl]-N-[4-methyl-3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate showed IC₅₀ of 1.20 and <0.10 µg/mL, resp., against the growth of K562 cells.


IT 404844-11-7P, N-[5-[(4-Chloromethylbenzoyl)amino]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidineamine 475587-06-5P,
 N-[3-(4-Chloromethylbenzoylamino)phenyl]-4-(3-pyridyl)-2-pyrimidineamine 796738-69-7P, N-[5-(4-Chloromethylbenzoylamino)-4-methylphenyl]-4-

(3-pyridyl)-2-pyrimidineamine 796738-70-0P, N-[4-(4-Chloromethylbenzoylamino)phenyl]-4-(3-pyridyl)-2-pyrimidineamine
 796738-74-4P, N-[4-(4-Chloromethylbenzoylamino)-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidineamine 796738-79-9P, N-[5-(4-Chloromethylbenzoylamino)-2-methoxyphenyl]-4-(3-pyridyl)-2-pyrimidineamine 796738-84-6P, N-[3-(4-Chloromethylbenzoylamino)-4-fluorophenyl]-4-(3-pyridyl)-2-pyrimidineamine
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of N-phenylpyrimidine-2-amine derivs. as anticancer agents)


RN 404844-11-7 CAPLUS

CN Benzamide, 4-(chloromethyl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 475587-06-5 CAPLUS

CN Benzamide, 4-(chloromethyl)-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-69-7 CAPLUS

CN Benzamide, 4-(chloromethyl)-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 796738-70-0 CAPLUS

CN Benzamide, 4-(chloromethyl)-N-[4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 796738-74-4 CAPLUS

CN Benzamide, 4-(chloromethyl)-N-[3-methyl-4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 796738-79-9 CAPLUS

CN Benzamide, 4-(chloromethyl)-N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 796738-84-6 CAPLUS

CN Benzamide, 4-(chloromethyl)-N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




IT 796738-23-3P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 796738-28-8P, 4-(4-Methylpiperazin-1-ylaminomethyl)-N-[2-methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]aminophenyl]benzamide 796738-30-2P
 , 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[4-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-34-6P, 4-(4-Methylpiperazin-1-ylaminomethyl)-N-[3-[4-(pyridin-3-yl)pyrimidin-2-yl]aminophenyl]benzamide
 796738-36-8P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[3-methyl-4-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 796738-38-0P, 4-(4-Methylpiperazin-1-ylaminomethyl)-N-[3-methyl-4-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-42-6P
 , 4-(4-Methylpiperazin-1-ylaminomethyl)-N-[4-methoxy-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-50-6P,
 4-(4-Methylpiperazin-1-ylaminomethyl)-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-52-8P,
 4-(4-Methylpiperazin-1-ylaminomethyl)-N-[4-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 804554-76-5P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-

yl]amino]phenyl]benzamide methanesulfonate 804554-78-7P,
 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[2-methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-79-8P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[4-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-81-2P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-82-3P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[3-methyl-4-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-83-4P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[3-methyl-4-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-85-6P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[4-methoxy-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-88-9P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-89-0P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[4-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-93-6P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[4-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide acetate
 804554-95-8P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide acetate
 804554-96-9P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[4-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide acetate
 804554-97-0P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[4-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide hydrochloride
 804554-98-1P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide hydrochloride
 804554-99-2P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[4-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide hydrochloride
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-phenylpyrimidine-2-amine derivs. as anticancer agents)


RN 796738-23-3 CAPLUS

CN Benzamide, 4-[[[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 796738-28-8 CAPLUS

CN Benzamide, 4-[[[(4-methyl-1-piperazinyl)amino]methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 796738-30-2 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 796738-34-6 CAPLUS

CN Benzamide, 4-[[(4-methyl-1-piperazinyl)amino]methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 796738-36-8 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-methyl-4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 796738-38-0 CAPLUS


CN Benzamide, 4-[[(4-methyl-1-piperazinyl)amino]methyl]-N-[3-methyl-4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 796738-42-6 CAPLUS
 CN Benzamide, N-[4-methoxy-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(4-methyl-1-piperazinyl)amino]methyl]- (CA INDEX NAME)



RN 796738-50-6 CAPLUS
 CN Benzamide, N-[2-fluoro-5-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(4-methyl-1-piperazinyl)amino]methyl]- (CA INDEX NAME)




RN 796738-52-8 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)



RN 804554-76-5 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-23-3
 CMF C29 H32 N8 O



CM 2

CRN 75-75-2
 CMF C H4 O3 S




RN 804554-78-7 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl-N-[2-methyl-5-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-28-8
 CMF C29 H32 N8 O



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 804554-79-8 CAPLUS
 CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-30-2
 CMF C29 H31 N7 O



CM 2


CRN 75-75-2
 CMF C H4 O3 S




RN 804554-81-2 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-34-6
 CMF C28 H30 N8 O




CM 2


CRN 75-75-2
CMF C H4 O3 S

RN 804554-82-3 CAPLUS
 CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-methyl-4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-36-8
CMF C30 H33 N7 O

CM 2


CRN 75-75-2
CMF C H4 O3 S

RN 804554-83-4 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[3-methyl-4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-38-0
CMF C29 H32 N8 O



CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 804554-85-6 CAPLUS

CN Benzamide, N-[4-methoxy-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(4-methyl-1-piperazinyl)amino]methyl-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 796738-42-6
CMF C29 H32 N8 O2



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 804554-88-9 CAPLUS

CN Benzamide, N-[2-fluoro-5-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)amino]methyl-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-50-6


CMF C28 H29 F N8 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 804554-89-0 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl-N-[4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-52-8

CMF C28 H30 N8 O




CM 2


CRN 75-75-2
CMF C H4 O3 S

RN 804554-93-6 CAPLUS
 CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-30-2
CMF C29 H31 N7 O

CM 2


CRN 64-19-7
CMF C2 H4 O2

RN 804554-95-8 CAPLUS
 CN Benzamide, 4-[[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[[4-(3-

pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monoacetate (9CI) (CA INDEX
NAME)


CM 1

CRN 796738-23-3
CMF C29 H32 N8 O



CM 2

CRN 64-19-7
CMF C2 H4 O2




RN 804554-96-9 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl-N-[4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monoacetate (9CI) (CA INDEX
NAME)


CM 1

CRN 796738-52-8
CMF C28 H30 N8 O




CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 804554-97-0 CAPLUS


CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 804554-98-1 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 804554-99-2 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


L10 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:996162 CAPLUS
 DN 141:424205
 TI New N-phenyl-2-pyrimidine-amine derivatives related to imatinib mesylate, useful as antitumor agents, and process for their preparation
 IN Kim, Dong-Yeon; Kim, Jae-Gun; Cho, Dae-Jin; Lee, Gong-Yeal; Kim, Hong-Youb; Woo, Seok-Hun; Kim, Yong-Seok; Bae, Woo-chul; Lee, Sun-Ahe; Han, Byoung-Cheol
 PA Il Yang Pharm. Co. Ltd., S. Korea
 SO PCT Int. Appl., 55 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004099187	A1	20041118	WO 2004-KR611	20040319
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	KR 2004095155	A	20041112	KR 2004-17594	20040316
PRAI	KR 2003-28669	A	20030506		


OS MARPAT 141:424205
 AB The invention relates to N-phenyl-2-pyrimidine-amine derivs. and their salts, which show superior action against lung cancer, gastric cancer, colon cancer, pancreatic cancer, hepatoma, prostatic cancer, breast cancer, chronic or acute leukemia, hematol. malignancy, encephalophyma, bladder cancer, rectal cancer, or cervical cancer, etc., in warm-blooded animals. The invention also relates to a process for preparing the compds., and to pharmaceutical compns. for the treatment of cancer, etc., which comprise the compds. as active ingredients, together with pharmaceutically acceptable inert carriers. Specifically claimed are compds. I and salts [wherein: R1 = 3-pyridyl or 4-pyridyl; R2, R3 = (independently) H or lower alkyl; R6 or R7 = -NHCO-p-C6H4-CH2XnR9; X = O or NH; n = 0-1; R9 = C5-10 aliphatic, or 5- to 7-membered (un)saturated monocycle, or a bi- or tricyclic radical optionally combined with a benzene ring, each with 1-3 N/O/S heteroatoms, or (homo)piperazinyl substituted by lower alkyl; 1-2 of R4, R5, R6/R7, and R8 = halo, lower alkyl, or lower alkoxy; others = H; provided that when R6 or R7 = said radical and n = 0 and R9 = 4-methylpiperazinyl, then one or more of R4, R5, R6/R7, and R8 is halo]. For example, 3-acetylpyridine was converted in 3 steps to N-(2-methyl-5-nitrophenyl)-4-(3-pyridyl)-2-pyrimidineamine. This nitro compound was reduced to the amine with SnCl₂, and the amine was amidated with 4-(ClCH₂)C₆H₄COCl. The obtained 4-(chloromethyl)benzamide derivative was coupled with 1-amino-4-methylpiperazine to give invention compound II, which was converted to the methanesulfonate salt (III). The latter was more than 5-fold more potent than imatinib mesylate against the human CML cell line K562, and was at least as active against other cell lines. Other compds. I showed different spectra of superiority to imatinib mesylate against the various cancer cell lines. Compound IV (mesylate) had excellent, dose-related therapeutic activity against sarcoma-180 in ICR mice, giving an inhibition ratio of 63.0% at 50 mg/kg i.v. In an oral

pharmacokinetic assay in rats, III roughly matched the performance of imatinib mesylate (Tmax, Cmax, and AUC) at half the dosage. III also showed no acute toxicity toward mice at a dose of 2000 mg/kg orally. IV mesylate had an i.v. LD50 of 75-100 mg/kg in mice, still much safer than cisplatin (11 mg/kg i.v.). Although several compds. I are preferred with respect to protein kinase inhibition (no data), II is particularly preferred. Therefore III and IV mesylate are expected to be new and potent therapeutic agents for the treatment of the aforementioned cancers, in addition to CML.

- IT 796738-23-3P, 4-[[[4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 796738-30-2P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)
- RN 796738-23-3 CAPLUS
- CN Benzamide, 4-[[[4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



- RN 796738-30-2 CAPLUS
 CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




- IT 796738-24-4P, 4-[[[4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-31-3P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)
- RN 796738-24-4 CAPLUS

CN Benzamide, 4-[[[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-23-3
CMF C29 H32 N8 O



CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 796738-31-3 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-30-2
CMF C29 H31 N7 O



CM 2


CRN 75-75-2
CMF C H4 O3 S



IT 796738-28-8P, 4-[(4-Methylpiperazin-1-yl)amino]methyl]-N-[2-methyl-5-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide
 796738-34-6P, 4-[(4-Methylpiperazin-1-yl)amino]methyl]-N-[3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide 796738-36-8P
 , 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[3-methyl-4-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide 796738-38-0P,
 4-[(4-Methylpiperazin-1-yl)amino]methyl]-N-[3-methyl-4-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide 796738-42-6P,
 4-[(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methoxy-3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide 796738-50-6P,
 4-[(4-Methylpiperazin-1-yl)amino]methyl]-N-[2-fluoro-5-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide 796738-52-8P,
 4-[(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)


RN 796738-28-8 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[2-methyl-5-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 796738-34-6 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 796738-36-8 CAPLUS


CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-methyl-4-[(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 796738-38-0 CAPLUS
 CN Benzamide, 4-[[[(4-methyl-1-piperazinyl)amino]methyl]-N-[3-methyl-4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 796738-42-6 CAPLUS
 CN Benzamide, N-[4-methoxy-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(4-methyl-1-piperazinyl)amino]methyl- (CA INDEX NAME)




RN 796738-50-6 CAPLUS
 CN Benzamide, N-[2-fluoro-5-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(4-methyl-1-piperazinyl)amino]methyl- (CA INDEX NAME)




RN 796738-52-8 CAPLUS
 CN Benzamide, 4-[[[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)



- IT 796738-29-9P, 4-[(4-Methylpiperazin-1-yl)amino]methyl-N-[2-methyl-5-[(4-pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-35-7P, 4-[(4-Methylpiperazin-1-yl)amino]methyl-N-[3-[(4-pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-37-9P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[3-methyl-4-[(4-pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-39-1P, 4-[(4-Methylpiperazin-1-yl)amino]methyl-N-[3-methyl-4-[(4-pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-43-7P, 4-[(4-Methylpiperazin-1-yl)amino]methyl-N-[4-methoxy-3-[(4-pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-51-7P, 4-[(4-Methylpiperazin-1-yl)amino]methyl-N-[2-fluoro-5-[(4-pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-53-9P, 4-[(4-Methylpiperazin-1-yl)amino]methyl-N-[4-[(4-pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-60-8P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-[(4-pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide acetate 796738-62-0P, 4-[(4-Methylpiperazin-1-yl)amino]methyl-N-[4-methyl-3-[(4-pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide acetate 796738-63-1P, 4-[(4-Methylpiperazin-1-yl)amino]methyl-N-[4-[(4-pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide acetate 796738-64-2P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-[(4-pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide hydrochloride 796738-65-3P, 4-[(4-Methylpiperazin-1-yl)amino]methyl-N-[4-methyl-3-[(4-pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide hydrochloride 796738-66-4P, 4-[(4-Methylpiperazin-1-yl)amino]methyl-N-[4-[(4-pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide hydrochloride
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)
- RN 796738-29-9 CAPLUS
- CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl-N-[2-methyl-5-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)
- CM 1
- CRN 796738-28-8
- CMF C29 H32 N8 O




CM 2


CRN 75-75-2
CMF C H4 O3 S

RN 796738-35-7 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-34-6
CMF C28 H30 N8 O

CM 2

CRN 75-75-2
CMF C H4 O3 S


RN 796738-37-9 CAPLUS
 CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-methyl-

10/528,913

4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI)
(CA INDEX NAME)


CM 1

CRN 796738-36-8
CMF C30 H33 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 796738-39-1 CAPLUS

CN Benzamide, 4-[[(4-methyl-1-piperazinyl)amino]methyl]-N-[3-methyl-4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 796738-38-0
CMF C29 H32 N8 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-43-7 CAPLUS

CN Benzamide, N-[4-methoxy-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)amino]methyl-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-42-6


CMF C29 H32 N8 O2



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-51-7 CAPLUS

CN Benzamide, N-[2-fluoro-5-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)amino]methyl-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-50-6

CMF C28 H29 F N8 O




CM 2


CRN 75-75-2
CMF C H4 O3 S

RN 796738-53-9 CAPLUS
 CN Benzamide, 4-[[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-52-8
CMF C28 H30 N8 O

CM 2


CRN 75-75-2
CMF C H4 O3 S

RN 796738-60-8 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, acetate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-30-2
CMF C29 H31 N7 O



CM 2

CRN 64-19-7
CMF C2 H4 O2




RN 796738-62-0 CAPLUS

CN Benzamide, 4-[[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, acetate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-23-3
CMF C29 H32 N8 O



CM 2

CRN 64-19-7
CMF C2 H4 O2




RN 796738-63-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, acetate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-52-8


CMF C28 H30 N8 O



CM 2


CRN 64-19-7

CMF C2 H4 O2



RN 796738-64-2 CAPLUS


CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 796738-65-3 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 796738-66-4 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl-N-[4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl


IT 404844-11-7P, N-[5-[(4-Chloromethyl)benzoyl]amino]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidineamine 475587-06-5P, N-[3-[(4-Chloromethyl)benzoyl]amino]phenyl]-4-(3-pyridyl)-2-pyrimidineamine 796738-69-7P, N-[5-[(4-Chloromethyl)benzoyl]amino]-4-methylphenyl]-4-(3-pyridyl)-2-pyrimidineamine 796738-70-0P, N-[4-[(4-Chloromethyl)benzoyl]amino]phenyl]-4-(3-pyridyl)-2-pyrimidineamine 796738-74-4P, N-[4-[(4-Chloromethyl)benzoyl]amino]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidineamine 796738-79-9P, N-[5-[(4-Chloromethyl)benzoyl]amino]-2-methoxyphenyl]-4-(3-pyridyl)-2-pyrimidineamine 796738-84-6P, N-[3-[(4-Chloromethyl)benzoyl]amino]-4-fluorophenyl]-4-(3-pyridyl)-2-pyrimidineamine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)

RN 404844-11-7 CAPLUS


CN Benzamide, 4-(chloromethyl)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 475587-06-5 CAPLUS
 CN Benzamide, 4-(chloromethyl)-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-69-7 CAPLUS
 CN Benzamide, 4-(chloromethyl)-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 796738-70-0 CAPLUS
 CN Benzamide, 4-(chloromethyl)-N-[4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 796738-74-4 CAPLUS
 CN Benzamide, 4-(chloromethyl)-N-[3-methyl-4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 796738-79-9 CAPLUS

CN Benzamide, 4-(chloromethyl)-N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 796738-84-6 CAPLUS

CN Benzamide, 4-(chloromethyl)-N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RE.CNT 4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 23 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:996161 CAPLUS

DN 141:424204

TI New N-phenyl-2-pyrimidine-amine derivatives related to imatinib mesylate, useful as antitumor agents, and process for the preparation thereof

IN Kim, Dong-Yeon; Kim, Jae-Gun; Cho, Dae-Jn; Lee, Gong-Yeal; Kim, Hong-Youb; Woo, Seok-Hun; Bae, Woo-chul; Lee, Sun-Ahe; Han, Byoung-Ceol

PA Il Yang Pharm Co., Ltd., S. Korea

SO PCT Int. Appl., 55 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004099186	A1	20041118	WO 2003-KR1029	20030526
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003232650	A1	20041126	AU 2003-232650	20030526
	KR 2004095155	A	20041112	KR 2004-17594	20040316
PRAI	KR 2003-28669	A	20030506		
	WO 2003-KR1029	W	20030526		

OS MARPAT 141:424204


AB The invention relates to N-phenyl-2-pyrimidine-amine derivs. and their salts, which show superior action against tumors, lung cancer, gastric cancer, etc., in warm-blooded animals. The invention also relates to a process for preparing the compds., and to pharmaceutical compns. for the prevention and treatment of cancer, etc., which comprise the compds. as active ingredients. Specifically claimed are compds. I and salts [wherein: R1 = 3-pyridyl or 4-pyridyl; R2, R3 = (independently) H or lower alkyl; R6 or R7 = -NHCO-p-C6H4-CH2XnR9; X = O or NH; n = 0-1; R9 = C5+ aliphatic or heterocycle, or (homo)piperazinyl substituted by lower alkyl; 1-2 of R4, R5, R6/R7, and R8 = halo, lower alkyl, or lower alkoxy; others = H; provided that when R6 or R7 = said radical and n = 0 and R9 = 4-methylpiperazinyl, then one or more of R4, R5, R6/R7, and R8 is halo]. For example, 3-acetylpyridine was converted in 3 steps to N-(2-methyl-5-nitrophenyl)-4-(3-pyridyl)-2-pyrimidineamine. This nitro compound was reduced to the amine with SnCl2, and the amine was amidated with 4-(ClCH2)C6H4COCl. The obtained 4-(chloromethyl)benzamide derivative was coupled with 1-amino-4-methylpiperazine to give invention compound II, which was converted to the methanesulfonate salt (III). The latter was more than 5-fold more potent than imatinib mesylate against the human CML cell line K562, and was at least as active against other cell lines. Other compds. I showed different spectra of superiority to imatinib mesylate against the various cancer cell lines. In an oral pharmacokinetic assay in rats, III roughly matched the performance of imatinib mesylate (Tmax, Cmax, and AUC) at half the dosage. III also showed no acute toxicity toward mice at a dose of 2000 mg/kg orally. Although several compds. I are preferred with respect to protein kinase inhibition (no data), II is particularly preferred.

IT 796738-23-3P, 4-[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide

796738-30-2P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-[(4-pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)


RN 796738-23-3 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)



RN 796738-30-2 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)



IT 796738-24-4P, 4-[[[4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate 796738-31-3P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)


RN 796738-24-4 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-23-3

CMF C29 H32 N8 O




CM 2


CRN 75-75-2
CMF C H4 O3 S

RN 796738-31-3 CAPLUS
 CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-30-2
CMF C29 H31 N7 O

CM 2

CRN 75-75-2
CMF C H4 O3 S

IT 796738-28-8P, 4-[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[2-


methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 796738-34-6P, 4-[[4-Methylpiperazin-1-yl)amino]methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-36-8P
 , 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[3-methyl-4-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-38-0P,
 4-[[4-Methylpiperazin-1-yl)amino]methyl]-N-[3-methyl-4-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-42-6P,
 4-[[4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methoxy-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-50-6P,
 4-[[4-Methylpiperazin-1-yl)amino]methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-52-8P,
 4-[[4-Methylpiperazin-1-yl)amino]methyl]-N-[4-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)


RN 796738-28-8 CAPLUS

CN Benzamide, 4-[[[4-methyl-1-piperazinyl)amino]methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 796738-34-6 CAPLUS

CN Benzamide, 4-[[[4-methyl-1-piperazinyl)amino]methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 796738-36-8 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-methyl-4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 796738-38-0 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[3-methyl-4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 796738-42-6 CAPLUS

CN Benzamide, N-[4-methoxy-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(4-methyl-1-piperazinyl)amino]methyl]- (CA INDEX NAME)




RN 796738-50-6 CAPLUS

CN Benzamide, N-[2-fluoro-5-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(4-methyl-1-piperazinyl)amino]methyl]- (CA INDEX NAME)



RN 796738-52-8 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




IT 796738-29-9P, 4-[(4-Methylpiperazin-1-yl)amino]methyl]-N-[2-methyl-5-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate 796738-35-7P, 4-[(4-Methylpiperazin-1-yl)amino]methyl]-N-[3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate 796738-37-9P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[3-methyl-4-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate 796738-39-1P, 4-[(4-Methylpiperazin-1-yl)amino]methyl]-N-[3-methyl-4-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate 796738-43-7P, 4-[(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methoxy-3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate 796738-51-7P, 4-[(4-Methylpiperazin-1-yl)amino]methyl]-N-[2-fluoro-5-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate 796738-53-9P, 4-[(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate 796738-60-8P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide acetate 796738-62-0P, 4-[(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide acetate 796738-63-1P, 4-[(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide acetate 796738-64-2P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide hydrochloride 796738-65-3P, 4-[(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide hydrochloride 796738-66-4P, 4-[(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide hydrochloride
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)

RN 796738-29-9 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[2-methyl-5-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-28-8
CMF C29 H32 N8 O

CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 796738-35-7 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-34-6


CMF C28 H30 N8 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-37-9 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-methyl-4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-36-8


CMF C30 H33 N7 O



CM 2


CRN 75-75-2
CMF C H4 O3 SRN 796738-39-1 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[3-methyl-4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-38-0
CMF C29 H32 N8 O

CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 796738-43-7 CAPLUS

CN Benzamide, N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[([(4-methyl-1-piperazinyl)amino]methyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-42-6


CMF C29 H32 N8 O2



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-51-7 CAPLUS

CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[([(4-methyl-1-piperazinyl)amino]methyl]-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-50-6

CMF C28 H29 F N8 O




CM 2


CRN 75-75-2
CMF C H4 O3 S

RN 796738-53-9 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-52-8
CMF C28 H30 N8 O

CM 2


CRN 75-75-2
CMF C H4 O3 S

RN 796738-60-8 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, acetate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-30-2
CMF C29 H31 N7 O



CM 2

CRN 64-19-7
CMF C2 H4 O2




RN 796738-62-0 CAPLUS

CN Benzamide, 4-[[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, acetate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-23-3
CMF C29 H32 N8 O



CM 2

CRN 64-19-7
CMF C2 H4 O2




RN 796738-63-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, acetate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-52-8


CMF C28 H30 N8 O



CM 2


CRN 64-19-7

CMF C2 H4 O2



RN 796738-64-2 CAPLUS


CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 796738-65-3 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 796738-66-4 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl-N-[4-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


IT 404844-11-7P, N-[5-[(4-Chloromethyl)benzoyl]amino]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidineamine 475587-06-5P, N-[3-[(4-Chloromethyl)benzoyl]amino]phenyl]-4-(3-pyridyl)-2-pyrimidineamine 796738-69-7P, N-[5-[(4-Chloromethyl)benzoyl]amino]-4-methylphenyl]-4-(3-pyridyl)-2-pyrimidineamine 796738-70-0P, N-[4-[(4-Chloromethyl)benzoyl]amino]phenyl]-4-(3-pyridyl)-2-pyrimidineamine 796738-74-4P, N-[4-[(4-Chloromethyl)benzoyl]amino]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidineamine 796738-79-9P, N-[5-[(4-Chloromethyl)benzoyl]amino]-2-methoxyphenyl]-4-(3-pyridyl)-2-pyrimidineamine 796738-84-6P, N-[3-[(4-Chloromethyl)benzoyl]amino]-4-fluorophenyl]-4-(3-pyridyl)-2-pyrimidineamine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)

RN 404844-11-7 CAPLUS


CN Benzamide, 4-(chloromethyl)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 475587-06-5 CAPLUS
 CN Benzamide, 4-(chloromethyl)-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-69-7 CAPLUS
 CN Benzamide, 4-(chloromethyl)-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 796738-70-0 CAPLUS
 CN Benzamide, 4-(chloromethyl)-N-[4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 796738-74-4 CAPLUS
 CN Benzamide, 4-(chloromethyl)-N-[3-methyl-4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 796738-79-9 CAPLUS

CN Benzamide, 4-(chloromethyl)-N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 796738-84-6 CAPLUS

CN Benzamide, 4-(chloromethyl)-N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RE.CNT 6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 24 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:964826 CAPLUS
 DN 141:410958
 TI Preparation of 2-phenylaminopyrimidine derivatives as tyrosine kinase inhibitors for treatment of cancers
 IN Chen, Guoqing P.
 PA USA
 SO U.S. Pat. Appl. Publ., 25 pp.
 CODEN: USXXCO

DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004224967	A1	20041111	US 2004-821382	20040409
US 7232825	B2	20070619		

PRAI US 2003-466883P P 20030502
 OS MARPAT 141:410958

AB The present invention relates to phenylaminopyrimidine derivs. (I) [X = O, S; Y = a direct bond, O, N, lower alkyl; Z = an aliphatic, cycloaliph., aryl or a heterocycl radical; R1 = heterocycl; R2 = H, halogen, halo-lower alkyl, lower alkyl, lower alkoxy; R3 = H, lower alkyl; R4 = oxy-lower alkylamino, lower alkoxy-lower alkylamino, oxyheterocycl, lower alkyl oxyheterocycl, oxy-lower alkylheterocycl, lower alkyl oxy-lower alkylheterocycl, halo-lower alkylamino, halo-lower alkylheterocycl, amino-lower alkylamino, lower alkylamino lower alkylamino, aminoheterocycl, lower alkylaminoheterocycl, amino-lower alkylheterocycl, lower alkylamino-lower alkylheterocycl] or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compns. containing them as active ingredient, methods for the treatment of disease states such as cancers associated with tyrosine kinases, especially Bcr-Abl, to their use as medicaments and to their use in the manufacture

of medicaments for use in the production of inhibition of tyrosine kinase reducing effects in warm-blooded animals such as humans. Thus, Mitsunobu reaction of N-(tert-butoxycarbonyl)aminoethanol and 4-hydroxy-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide in CH₂C₁₂ at room temperature for 4 h gave 4-[2-(tert-butoxycarbonylamino)ethoxy]-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide which was treated with 4 N HCl/dioxane, evaporated, mixed with NaHCO₃, and extracted with EtOAc

to give 4-(2-aminoethoxy)-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide. No biol. data for the compds. I were given.

IT 623900-99-2P, 4-Nitro-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide 791609-55-7P, 4-Hydroxy-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide 791609-57-9P, 4-[2-(tert-Butoxycarbonylamino)ethoxy]-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide 791609-64-8P, N-[4-Methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]-4-(1-benzylpyrrolidin-3-ylamino)benzamide 791609-70-6P, 4-[Fluoro(1-benzylpyrrolidin-3-ylamino)methyl]-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide 791609-83-1P, 4-(Aminomethyl)-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of 2-phenylaminopyrimidine derivs. as tyrosine kinase inhibitors for treatment of cancers)

RN 623900-99-2 CAPLUS


CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-

nitro- (9CI) (CA INDEX NAME)




RN 791609-55-7 CAPLUS

CN Benzamide, 4-hydroxy-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 791609-57-9 CAPLUS

CN Carbamic acid, [2-[4-[[[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]carbonyl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 791609-64-8 CAPLUS


CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(1-(phenylmethyl)-3-pyrrolidinyl)amino]- (CA INDEX NAME)




RN 791609-70-6 CAPLUS

CN Benzamide, 4-[fluoro[[1-(phenylmethyl)-3-pyrrolidinyl]amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



RN 791609-83-1 CAPLUS
 CN Benzamide, 4-(aminomethyl)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)



IT 791609-56-8P, 4-(2-Aminoethoxy)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]benzamide 791609-58-0P,
 N-[4-Methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(1-methylpyrrolidin-3-yl)amino]benzamide 791609-62-6P,
 N-[4-Methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(1-methylpyrrolidin-2-yl)methoxy]benzamide 791609-63-7P,
 N-[4-Methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-(pyrrolidin-3-ylamino)benzamide 791609-65-9P, 4-(Aminofluoromethyl)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]benzamide 791609-67-1P, 4-(Aminodifluoromethyl)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]benzamide 791609-68-2P,
 4-[Methyl(1-methylpyrrolidin-3-yl)amino]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]benzamide 791609-69-3P,
 4-[Fluoro[(1-methylpyrrolidin-3-yl)amino]methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]benzamide 791609-71-7P,
 4-[[2-(Dimethylamino)ethyl]amino]fluoromethyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]benzamide 791609-74-0P,
 4-[[2-(Dimethylamino)ethyl]amino]difluoromethyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]benzamide 791609-75-1P,
 4-[Fluoro[N-methyl(1-methylpyrrolidin-3-yl)amino]methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]benzamide 791609-76-2P,
 4-[Fluoro(pyrrolidin-3-ylamino)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]benzamide 791609-79-5P,
 4-[Difluoro[methyl(1-methylpyrrolidin-3-yl)amino]methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]benzamide 791609-80-8P,
 4-[Difluoro(1-methylpyrrolidin-3-ylamino)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]benzamide 791609-81-9P,
 4-[Difluoro(pyrrolidin-3-ylamino)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]benzamide 791609-82-0P,
 4-[[Methyl(1-methylpyrrolidin-3-yl)amino]methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]benzamide 791609-84-2P,
 4-[[1-Methylpyrrolidin-3-yl)amino]methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]benzamide 791609-85-3P,
 4-[(Pyrrolidin-3-ylamino)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]benzamide 791609-87-5P, 4-(2-Aminoethoxy)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]benzamide


methanesulfonate 791609-88-6P, N-[4-Methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]-4-[(1-methylpyrrolidin-3-yl)amino]benzamide methanesulfonate 791609-90-0P,
 N-[4-Methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]-4-[(1-methylpyrrolidin-2-yl)methoxy]benzamide methanesulfonate
 791609-91-1P, N-[4-Methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]-4-(pyrrolidin-3-ylamino)benzamide methanesulfonate
 791609-92-2P, 4-(Aminofluoromethyl)-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 791609-94-4P, 4-(Aminodifluoromethyl)-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 791609-95-5P, 4-[Methyl(1-methylpyrrolidin-3-yl)amino]-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 791609-97-7P, 4-[Fluoro(1-methylpyrrolidin-3-ylamino)methyl]-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide
 methanesulfonate 791609-98-8P, 4-[[[2-(Dimethylamino)ethyl]amino]fluoromethyl]-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 791610-01-0P, 4-[[[2-(Dimethylamino)ethyl]amino]difluoromethyl]-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide
 methanesulfonate 791610-02-1P, 4-[Fluoro[methyl(1-methylpyrrolidin-3-yl)amino]methyl]-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 791610-03-2P,
 4-[Fluoro(pyrrolidin-3-ylamino)methyl]-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 791610-06-5P, 4-[Difluoro[methyl(1-methylpyrrolidin-3-yl)amino]methyl]-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 791610-07-6P,
 4-[Difluoro(1-methylpyrrolidin-3-ylamino)methyl]-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 791610-08-7P, 4-[Difluoro(pyrrolidin-3-ylamino)methyl]-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 791610-09-8P, 4-[Methyl(1-methylpyrrolidin-3-yl)amino]methyl]-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide
 methanesulfonate 791610-10-1P, 4-[[[1-Methylpyrrolidin-3-yl]amino]methyl]-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 791610-11-2P,
 4-[(Pyrrolidin-3-ylamino)methyl]-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 2-phenylaminopyrimidine derivs. as tyrosine kinase inhibitors for treatment of cancers)

RN

791609-56-8 CAPLUS


CN

Benzamide, 4-(2-aminoethoxy)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 791609-58-0 CAPLUS

CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(1-methyl-3-pyrrolidinyl)amino]- (CA INDEX NAME)




RN 791609-62-6 CAPLUS

CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(1-methyl-2-pyrrolidinyl)methoxy]- (CA INDEX NAME)




RN 791609-63-7 CAPLUS

CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-(3-pyrrolidinylamino)- (CA INDEX NAME)




RN 791609-65-9 CAPLUS

CN Benzamide, 4-(aminofluoromethyl)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 791609-67-1 CAPLUS

CN Benzamide, 4-(aminodifluoromethyl)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)



RN 791609-68-2 CAPLUS


CN Benzamide, 4-[methyl(1-methyl-3-pyrrolidinyl)amino]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 791609-69-3 CAPLUS

CN Benzamide, 4-[fluoro[(1-methyl-3-pyrrolidinyl)amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 791609-71-7 CAPLUS

CN Benzamide, 4-[[[2-(dimethylamino)ethyl]amino]fluoromethyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 791609-74-0 CAPLUS


CN Benzamide, 4-[[[2-(dimethylamino)ethyl]amino]difluoromethyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 791609-75-1 CAPLUS

CN Benzamide, 4-[[[2-(dimethylamino)ethyl]amino]methyl]methyl-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 791609-76-2 CAPLUS

CN Benzamide, 4-[fluoro(3-pyrrolidinylamino)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 791609-79-5 CAPLUS

CN Benzamide, 4-[difluoro[methyl(1-methyl-3-pyrrolidinyl)amino]methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 791609-80-8 CAPLUS

CN Benzamide, 4-[difluoro[(1-methyl-3-pyrrolidinyl)amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 791609-81-9 CAPLUS

CN Benzamide, 4-[difluoro(3-pyrrolidinylamino)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 791609-82-0 CAPLUS

CN Benzamide, 4-[[methyl(1-methyl-3-pyrrolidinyl)amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 791609-84-2 CAPLUS

CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(1-methyl-3-pyrrolidinyl)amino]methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 791609-85-3 CAPLUS

CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(3-pyrrolidinylamino)methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 791609-87-5 CAPLUS

CN Benzamide, 4-(2-aminoethoxy)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 791609-56-8


CMF C25 H24 N6 O2



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 791609-88-6 CAPLUS
 CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(1-methyl-3-pyrrolidinyl)amino]-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 791609-58-0
 CMF C28 H29 N7 O



CM 2


CRN 75-75-2
 CMF C H4 O3 S




RN 791609-90-0 CAPLUS
 CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(1-methyl-2-pyrrolidinyl)methoxy]-, methanesulfonate (9CI) (CA INDEX)

NAME)

CM 1

CRN 791609-62-6
CMF C29 H30 N6 O2


CM 2

CRN 75-75-2
CMF C H4 O3 S


RN 791609-91-1 CAPLUS
 CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-(3-pyrrolidinylamino)-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 791609-63-7
CMF C27 H27 N7 O




CM 2

CRN 75-75-2
CMF C H4 O3 S


RN 791609-92-2 CAPLUS
 CN Benzamide, 4-(aminofluoromethyl)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 791609-65-9
CMF C24 H21 F N6 O

CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 791609-94-4 CAPLUS
 CN Benzamide, 4-(aminodifluoromethyl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 791609-67-1
 CMF C24 H20 F2 N6 O



CM 2


CRN 75-75-2
 CMF C H4 O3 S




RN 791609-95-5 CAPLUS
 CN Benzamide, 4-[methyl(1-methyl-3-pyrrolidinyl)amino]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 791609-68-2
 CMF C29 H31 N7 O




CM 2

CRN 75-75-2
CMF C H4 O3 SRN 791609-97-7 CAPLUS
CN Benzamide, 4-[fluoro[(1-methyl-3-pyrrolidinyl)amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI)
(CA INDEX NAME)


CM 1

CRN 791609-69-3
CMF C29 H30 F N7 O


PAGE 1-A



PAGE 2-A




CM 2


CRN 75-75-2
CMF C H4 O3 S

RN 791609-98-8 CAPLUS
 CN Benzamide, 4-[[[2-(dimethylamino)ethyl]amino]fluoromethyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI)
 (CA INDEX NAME)

CM 1

CRN 791609-71-7
CMF C28 H30 F N7 O


CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 791610-01-0 CAPLUS


CN Benzamide, 4-[[[2-(dimethylamino)ethyl]amino]difluoromethyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI)
(CA INDEX NAME)

CM 1

CRN 791609-74-0
CMF C28 H29 F2 N7 O

CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 791610-02-1 CAPLUS


CN Benzamide, 4-[fluoro[methyl(1-methyl-3-pyrrolidinyl)amino]methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 791609-75-1

CMF C30 H32 F N7 O

PAGE 1-A




PAGE 2-A



CM 2

CRN 75-75-2
 CMF C H4 O3 S




RN 791610-03-2 CAPLUS
 CN Benzamide, 4-[fluoro(3-pyrrolidinylamino)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 791609-76-2
 CMF C28 H28 F N7 O


PAGE 1-A



PAGE 2-A



CM 2


CRN 75-75-2
CMF C H4 O3 S

RN 791610-06-5 CAPLUS
 CN Benzamide, 4-[difluoro[methyl(1-methyl-3-pyrrolidinyl)amino]methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 791609-79-5
CMF C30 H31 F2 N7 O


PAGE 1-A



PAGE 2-A




CM 2

CRN 75-75-2
CMF C H4 O3 SRN 791610-07-6 CAPLUS
CN Benzamide, 4-[difluoro[(1-methyl-3-pyrrolidinyl)amino]methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, methanesulfonate (9CI)
(CA INDEX NAME)


CM 1

CRN 791609-80-8
CMF C29 H29 F2 N7 O


PAGE 1-A



PAGE 2-A



CM 2


CRN 75-75-2
CMF C H4 O3 S

RN 791610-08-7 CAPLUS
 CN Benzamide, 4-[difluoro(3-pyrrolidinylamino)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 791609-81-9
CMF C28 H27 F2 N7 O


PAGE 1-A



PAGE 2-A



CM 2


CRN 75-75-2
CMF C H4 O3 S

RN 791610-09-8 CAPLUS
 CN Benzamide, 4-[[methyl(1-methyl-3-pyrrolidinyl)amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI)
 (CA INDEX NAME)


CM 1

CRN 791609-82-0
CMF C30 H33 N7 O


PAGE 1-A



PAGE 2-A



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 791610-10-1 CAPLUS


CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(1-methyl-3-pyrrolidinyl)amino]methyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 791609-84-2

CMF C29 H31 N7 O

PAGE 1-A




PAGE 2-A



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 791610-11-2 CAPLUS


CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(3-pyrrolidinylamino)methyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 791609-85-3

CMF C28 H29 N7 O

PAGE 1-A



PAGE 2-A




CM 2

CRN 75-75-2


CMF C H4 O3 S

10/528,913



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 25 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:954402 CAPLUS
 DN 142:147823
 TI Efficient optimization strategy for marginal hits active against abl tyrosine kinases
 AU Tkachenko, Sergey E.; Okun, Ilya; Balakin, Konstantin V.; Petersen, Charles E.; Ivanenkov, Yan A.; Savchuk, Nikolay P.; Ivashchenko, Andrey A.
 CS Chemical Diversity Labs, Inc., San Diego, CA, 92121, USA
 SO Current Drug Discovery Technologies (2004), 1(3), 201-210
 CODEN: CDDTAF; ISSN: 1570-1638
 PB Bentham Science Publishers Ltd.
 DT Journal
 LA English
 AB Primary high-throughput screening of com. available small mols. collections often results in hit compds. with unfavorable ADME/Tox properties and low IP potential. These issues are addressed empirically at follow-up lead development and optimization stages. In this work, we describe a rational approach to the optimization of hit compds. discovered during screening of a kinase focused library against abl tyrosine kinase. The optimization strategy involved application of modern chemoinformatics techniques, such as automatic bioisosteric transformation of the initial hits, efficient solution-phase combinatorial synthesis, and advanced methods of knowledge-based libraries design.
 IT 152459-94-4, CGP-53716
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (efficient optimization strategy for marginal hits active against abl tyrosine kinases)
 RN 152459-94-4 CAPLUS
 CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 26 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:533970 CAPLUS
 DN 141:65088
 TI Methods and compositions for the prevention or treatment of neoplasia comprising a COX-2 inhibitor in combination with an epidermal growth factor receptor antagonist
 IN Masferrer, Jaime
 PA Pharmacia Corporation, USA
 SO U.S. Pat. Appl. Publ., 103 pp., Cont.-in-part of U.S. Ser. No. 470,951.
 CODEN: USXXCO

DT Patent
 LA English

FAN.CNT 21

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004127470	A1	20040701	US 2003-651916	20030829
	EP 1522313	A1	20050413	EP 2004-26577	19991222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO, CY				
	WO 2005037259	A2	20050428	WO 2004-US27574	20040825
	WO 2005037259	A3	20050804		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004210578	A1	20041007	AU 2004-210578	20040910

PRAI US 1998-113786P P 19981223
 US 1999-470951 B2 19991222
 US 1999-385214 A 19990827
 AU 2000-25936 A3 19991222
 EP 1999-968939 A3 19991222
 US 2003-651916 A 20030829


AB The present invention relates to a novel method of preventing and/or treating neoplasia disorders in a subject that is in need of such prevention or treatment by administering to the subject at least one COX-2 inhibitor in combination with an EGF receptor antagonist. Compns., pharmaceutical compns. and kits are also described.

IT 152459-94-4, CGP-53716

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
 THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (as EGFR antagonist; COX-2 inhibitor in combination with epidermal growth factor receptor antagonist for prevention or treatment of neoplasia)

RN 152459-94-4 CAPLUS

CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (CA INDEX NAME)



L10 ANSWER 27 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:287838 CAPLUS
 DN 140:321373

TI Preparation of novel pyrimidine amides as protein kinase inhibitors
 IN Manley, Paul William; Breitenstein, Werner; Jacob, Sandra; Furet, Pascal
 PA Novartis Ag, Switz.; Novartis Pharma GmbH
 SO PCT Int. Appl., 57 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004029038	A1	20040408	WO 2003-EP10724	20030926
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
	RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
	CA 2499822	A1	20040408	CA 2003-2499822	20030926
	AU 2003270277	A1	20040419	AU 2003-270277	20030926
	AU 2003270277	B2	20070823		
	EP 1546127	A1	20050629	EP 2003-750639	20030926
	EP 1546127	B1	20070808		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003014797	A	20050726	BR 2003-14797	20030926
	CN 1684951	A	20051019	CN 2003-823213	20030926
	JP 2006508064	T	20060309	JP 2004-539039	20030926
	AT 369355	T	20070815	AT 2003-750639	20030926
	ZA 2005002304	A	20060426	ZA 2005-2304	20050318
	MX 2005PA03253	A	20050608	MX 2005-PA3253	20050323
	IN 2005CN00464	A	20070406	IN 2005-CN464	20050323
	NO 2005001966	A	20050422	NO 2005-1966	20050422
	US 2006142577	A1	20060629	US 2006-528913	20060105
PRAI	GB 2002-22514	A	20020927		
	WO 2003-EP10724	W	20030926		

OS MARPAT 140:321373

AB The title substituted N-(3-benzoylaminophenyl)-4-pyridyl-2-pyrimidinamines [I; R1 = H and R2 = NR5R6, or R1 = NR5R6 and R2 = H; R3 = alkyl, fluoroalkyl, hydroxyalkyl, carbamoyl; R4 = H, alkyl, halo; R5 and R6 = H, alkyl, hydroxyalkyl, etc. or NR5R6 = (un)substituted (un)saturated 5-7 membered ring optionally containing heteroatoms], useful for the therapy of a disease which responds to an inhibition of protein kinase activity, especially

a neoplastic disease (e.g., leukemia), were prepared and formulated. Thus, amidation of 4-methyl-N-[4-(3-pyridinyl)-2-pyrimidinyl]-1,3-benzenediamine with 4-diethylamino-3-(trifluoromethyl)benzoic acid (preparation given) afforded I [R1 = H; R2 = NEt2; R3 = CF3; R4 = Me] which showed IC50 of 50-100 nM against c-Abl and IC50 of 200-500 nM against Bcr-Abl (in vitro inhibition data).

IT 677704-35-7P 677704-36-8P 677704-37-9P
 677704-38-0P 677704-39-1P 677704-40-4P
 677704-41-5P 677704-42-6P 677704-43-7P
 677704-44-8P 677704-45-9P 677704-46-0P
 677704-47-1P 677704-48-2P 677704-49-3P

App.


677704-50-6P 677704-51-7P 677704-52-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel N-[3-(pyrimidin-2-ylamino)phenyl] benzamides as protein kinase inhibitors)


RN 677704-35-7 CAPLUS

CN Benzamide, 4-(diethylamino)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 677704-36-8 CAPLUS

CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-(1-pyrrolidinyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 677704-37-9 CAPLUS

CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-(4-morpholinyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 677704-38-0 CAPLUS

CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-(1-piperidinyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 677704-39-1 CAPLUS

CN Benzamide, 4-(4-methyl-1-piperazinyl)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 677704-40-4 CAPLUS

CN Benzamide, 4-(1H-imidazol-1-yl)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 677704-41-5 CAPLUS

CN Benzamide, 4-(2-methyl-1H-imidazol-1-yl)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 677704-42-6 CAPLUS

CN Benzamide, 4-(4-methyl-1H-imidazol-1-yl)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 677704-43-7 CAPLUS

CN Benzamide, 4-(2,4-dimethyl-1H-imidazol-1-yl)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 677704-44-8 CAPLUS

CN Benzamide, 3-(1H-imidazol-1-yl)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 677704-45-9 CAPLUS

CN Benzamide, 3-(2-methyl-1H-imidazol-1-yl)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 677704-46-0 CAPLUS


CN Benzamide, 3-(4-methyl-1H-imidazol-1-yl)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 677704-47-1 CAPLUS
 CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-3-(4-morpholinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 677704-48-2 CAPLUS
 CN Benzamide, 3-(4-methyl-1-piperazinyl)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 677704-49-3 CAPLUS
 CN Benzamide, 4-[(2-(dimethylamino)ethyl)methylamino]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 677704-50-6 CAPLUS
 CN Benzamide, 4-[methyl(1-methyl-4-piperidinyl)amino]-N-[4-methyl-3-[(4-(3-

pyridinyl)-2-pyrimidinyl]amino]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 677704-51-7 CAPLUS

CN Benzamide, 3-(ethylamino)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 677704-52-8 CAPLUS

CN Benzamide, 3-(acetylamino)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:20664 CAPLUS
 DN 140:77165
 TI Preparation of 4-[(4-methylpiperazin-1-yl)methyl]benzamide for treatment of leukemia
 IN Asaki, Tetsuo; Hamamoto, Taisuke; Sugiyama, Yukiteru
 PA Nippon Shinyaku Co., Ltd., Japan
 SO PCT Int. Appl., 102 pp.
 CODEN: PIXXD2

DT Patent
 LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004002963	A1	20040108	WO 2003-JP8192	20030627
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2490907	A1	20040108	CA 2003-2490907	20030627
	AU 2003246100	A1	20040119	AU 2003-246100	20030627
	BR 2003012288	A	20050412	BR 2003-12288	20030627
	EP 1533304	A1	20050525	EP 2003-738555	20030627
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1678590	A	20051005	CN 2003-820146	20030627
	MX 2004PA12845	A	20050224	MX 2004-PA12845	20041216
	US 2006014742	A1	20060119	US 2004-519722	20041228
PRAI	JP 2002-189269	A	20020628		
	JP 2002-305146	A	20021018		
	JP 2002-377937	A	20021226		
	WO 2003-JP8192	W	20030627		

OS MARPAT 140:77165

AB The title compds. I [wherein R1 = saturate cyclic amino, alkylamino, or dialkylamino; R2 = alkyl, halo, haloalkyl, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, acyl, amino, alkylamino, dialkylamino, NO₂, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, or CN; R3 = H, halo, or alkoxy; Het1 = pyridyl, Ph, pyrimidyl, pyrazinyl, or triazinyl; Het2 = pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, or 1,2-dihydropyridazinyl; etc.] or salts thereof are prepared as BCR-ABL tyrosine kinase inhibitors, and are useful for the treatment of leukemia (no data). For example, the compound II was prepared in a multi-step synthesis. II showed inhibitory activities with IC₅₀ of 0.0008 and 3.99 μM against cell proliferation of K562 and U937, resp., in cow. Formulations containing I as an active ingredient were also described.


IT 641615-11-4P 641615-12-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of [(piperazinyl)methyl]benzamides for treatment of leukemia)


RN 641615-11-4 CAPLUS

CN Benzamide, 3-bromo-4-[(dimethylamino)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 641615-12-5 CAPLUS



CN Benzamide, 3-bromo-4-[(diethylamino)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 2


THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:738968 CAPLUS
 DN 139:358017
 TI Kinases, Homology Models, and High Throughput Docking
 AU Diller, David J.; Li, Rixin
 CS Pharmacopeia, Inc., Princeton, NJ, 08543-5350, USA
 SO Journal of Medicinal Chemistry (2003), 46(22), 4638-4647
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 AB With the many protein sequences coming from the genome sequencing projects, it is unlikely that the authors will ever have an atomic resolution structure of every relevant protein. With high throughput crystallog., however, the authors will soon have representative structures for the vast majority of protein families. Thus the drug discovery and design process will rely heavily on protein modeling to address issues such as designing combinatorial libraries for an entire class of targets and engineering genome-wide selectivity over a target class. In this study the authors assess the value of high throughput docking into homol. models. To do this the authors dock a database of random compds. seeded with known inhibitors into homol. models of six different kinases. In five of the six cases the known inhibitors were enriched by factors of 4-5 in the top 5% of the overall scored and ranked compds. Furthermore, in the same five cases the known inhibitors were enriched by factors of 2-3 in the top 5% of the scored and ranked known kinase inhibitors, thus showing that the homol. models can pick up some of the crucial selectivity information.
 IT 152459-94-4D, derivs.
 RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
 (protein kinases and homol. models and high throughput docking in relation to drug discovery and design)
 RN 152459-94-4 CAPLUS
 CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (CA INDEX NAME)




RE.CNT 76 THERE ARE 76 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 30 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:689661 CAPLUS
 DN 139:374254
 TI Synthesis of pyrimidinopyridine-triazene conjugates targeted to abl tyrosine kinase
 AU Rachid, Zakaria; Katsoulas, Athanasia; Brahimi, Fouad; Jean-Claude, Bertrand Jacques
 CS Department of Medicine, Division of Medical Oncology, Cancer Drug Research Laboratory, McGill University/Royal Victoria Hospital, Montreal, QC, H3T 1C5, Can.
 SO Bioorganic & Medicinal Chemistry Letters (2003), 13(19), 3297-3300
 CODEN: BMCL8; ISSN: 0960-894X
 PB Elsevier Science B.V.
 DT Journal
 LA English
 OS CASREACT 139:374254
 AB The synthesis and abl tyrosine kinase inhibitory activities of alkyltriazenes conjugated to phenylaminopyrimidines are described. Significant abl inhibitory activities were observed only when a benzamido spacer was inserted between the 1,2,3-triazene chain and the 2-phenylaminopyridopyrimidine moiety.
 IT 623901-00-8P 623901-01-9P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (synthesis of pyrimidinopyridine-triazene conjugates targeted to abl tyrosine kinase and cytotoxicity structure activity)
 RN 623901-00-8 CAPLUS
 CN Benzamide, 4-amino-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 623901-01-9 CAPLUS
 CN Benzamide, 4-amino-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




IT 623901-02-0P 623901-03-1P 623901-04-2P
 623901-05-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (synthesis of pyrimidinopyridine-triazene conjugates targeted to abl tyrosine kinase and cytotoxicity structure activity)
 RN 623901-02-0 CAPLUS
 CN Benzamide, 4-[3-(2-methoxyethyl)-1-triazenyl]-N-[3-[[4-(3-pyridinyl)-2-

pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 623901-03-1 CAPLUS

CN Benzamide, 4-(3,3-dimethyl-1-triazenyl)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 623901-04-2 CAPLUS

CN Benzamide, 4-[3-(hydroxymethyl)-3-methyl-1-triazenyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 623901-05-3 CAPLUS

CN Benzamide, 4-[3-(2-chloroethyl)-3-methyl-1-triazenyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




IT 623900-98-1P 623900-99-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis of pyrimidinopyridine-triazene conjugates targeted to abl tyrosine kinase and cytotoxicity structure activity)


RN 623900-98-1 CAPLUS

CN Benzamide, 4-nitro-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 623900-99-2 CAPLUS

CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-nitro- (9CI) (CA INDEX NAME)



RE.CNT 26

THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:678606 CAPLUS
 DN 139:197709
 TI macrolide erythromycin conjugates of biologically active compounds, methods for their preparation and use, formulation, and pharmaceutical applications thereof
 IN Burnet, Michael; Guse, Jan-Hinrich; Gutke, Hans-Jurgen; Beck, Albert; Tsotsou, Georgia; Droste-Borel, Irina; Reichert, Jeannette; Luyten, Kattie; Busch, Maximilian; Wolff, Michael; Khobzaoui, Moussa; Margutti, Simona; Meindl, Thomas; Kim, Gene; Barker, Laurence
 PA Sympore G.m.b.H., Germany
 SO PCT Int. Appl., 183 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003070174	A2	20030828	WO 2003-US4609	20030214
	WO 2003070174	A3	20031113		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2476423	A1	20030828	CA 2003-2476423	20030214
	AU 2003219770	A1	20030909	AU 2003-219770	20030214
	EP 1483277	A2	20041208	EP 2003-716044	20030214
	R: AT, BE, CH, DE, DK, ES, FR, IE, SI, LT, LV, FI, RO, MK,				
	GB, GR, IT, LI, LU, NL, SE, MC, PT, CY, AL, TR, BG, CZ, EE, HU, SK				
	IN 2004CN01815	A	20060616	IN 2004-CN1815	20040813
	US 2005171342	A1	20050804	US 2005-504787	20050324
PRAI	US 2002-357434P	P	20020215		
	WO 2003-US4609	W	20030214		

OS MARPAT 139:197709

AB Erythromycin macrolide conjugates T-(L-C)m, wherein T is a transportophore, L is a bond or a linker having a mol. weight up to 240 dalton, C is a non-antibiotic therapeutic agent, and m is 1-8, in which the transportophore has an immune selectivity ratio of at least 2, the transportophore is covalently bonded to the non-antibiotic therapeutic agent via the bond or the linker, and the compound has an immune selectivity ratio of at least 2, useful for enhancing efficacy of a therapeutic agent. Thus, macrolide I (R = R1) was prepared in 76% yield via coupling of I (R = H) with diclofenac as antitumor and antibacterial agent and was tested in vitro for its cytotoxicity and immunosuppressive activity using a mouse skin transplant model.

IT 586412-38-6P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(macrolide erythromycin conjugates of biol. active compds. methods for their preparation and use formulation and pharmaceutical applications thereof)



RN 586412-38-6 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-


α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-2-O-[4-[[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]amino]carbonyl]phenyl]-1-piperazinyl]acetyl]- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




IT 586412-43-3P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (macrolide erythromycin conjugates of biol. active compds. methods for their preparation and use formulation and pharmaceutical applications thereof)

RN 586412-43-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[[[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]amino]carbonyl]phenyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



11/561,039

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

PAGE 2-A



10/528,913

L10 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:678605 CAPLUS
 DN 139:197708

TI macrolide erythromycin conjugates of biologically active compounds, methods for their preparation and use, formulation, and pharmaceutical applications thereof

IN Burnet, Michael; Guse, Jan-Hinrich; Kim, Gene; Beck, Albert; Tsotsou, Georgia; Droste-Borel, Irina; Barker, Laurence; Wolff, Michael; Gutke, Hans-Jurgen

PA Sympore G.m.b.H., Germany

SO PCT Int. Appl., 164 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003070173	A2	20030828	WO 2003-US4596	20030214
	WO 2003070173	A3	20031204		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003215245	A1	20030909	AU 2003-215245	20030214
	US 2004005641	A1	20040108	US 2003-367624	20030214
	EP 1483579	A2	20041208	EP 2003-711061	20030214
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	IN 2004CN01809	A	20060224	IN 2004-CN1809	20040813
	US 2006099660	A1	20060511	US 2005-504786	20050929
PRAI	US 2002-357589P	P	20020215		
	WO 2003-US4596	W	20030214		
OS	MARPAT 139:197708				
AB	Erythromycin macrolide conjugates T-(L-C) _m , wherein T is a transportophore, L is a bond or a linker having a mol. weight up to 240 dalton, C is a non-antibiotic therapeutic agent, and m is 1-8, in which the transportophore has an immune selectivity ratio of at least 2, the transportophore is covalently bonded to the non-antibiotic therapeutic agent via the bond or the linker, and the compound has an immune selectivity ratio of at least 2, useful for enhancing efficacy of a therapeutic agent. Thus, macrolide I (R = R ₁) was prepared in 76% yield via coupling of I (R = H) with diclofenac as antitumor and antibacterial agent and was tested in vitro for its cytotoxicity and immunosuppressive activity using a mouse skin transplant model.				
IT	586412-38-6P				
	RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(macrolide erythromycin conjugates of biol. active compds. methods for their preparation and use formulation and pharmaceutical applications thereof)				
RN	586412-38-6 CAPLUS				
CN	1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-				


10/528,913

ALL CITATIONS AVAILABLE IN THE RE FORMAT


3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-2-O-[[4-[4-[[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]amino]carbon
y1]phenyl]-1-piperazinyl]acetyl]- β -D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



10/528,913

PAGE 2-A




IT 586412-43-3P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (macrolide erythromycin conjugates of biol. active compds. methods for their preparation and use formulation and pharmaceutical applications thereof)

RN 586412-43-3 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[4-[[[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]amino]carbonyl]phenyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



10/528, 913

PAGE 2-A



L10 ANSWER 33 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:633685 CAPLUS
 DN 139:180080
 TI Preparation of N-(pyridin-3-ylpyrimidin-2-ylaminophenyl)benzamide derivatives
 IN Loiseleur, Olivier; Kaufmann, Daniel; Abel, Stephan; Buerger, Hans Michael; Meisenbach, Mark; Schmitz, Beat; Sedelmeier, Gottfried
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SO PCT Int. Appl., 38 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003066613	A1	20030814	WO 2003-EP1188	20030206
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR				
	CA 2474738	A1	20030814	CA 2003-2474738	20030206
	AU 2003244444	A1	20030902	AU 2003-244444	20030206
	AU 2003244444	B2	20070809		
	EP 1474408	A1	20041110	EP 2003-737319	20030206
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003007529	A	20041221	BR 2003-7529	20030206
	CN 1630648	A	20050622	CN 2003-803556	20030206
	JP 2005528340	T	20050922	JP 2003-565987	20030206
	NZ 534315	A	20070629	NZ 2003-534315	20030206
	CN 101016262	A	20070815	CN 2007-10086009	20030206
	IN 2004CN01716	A	20060224	IN 2004-CN1716	20040804
	MX 2004PA07642	A	20041110	MX 2004-PA7642	20040806
	NO 2004003685	A	20041105	NO 2004-3685	20040903
	US 2006142580	A1	20060629	US 2005-503538	20050120
	ZA 200405970	A	20060531	ZA 2004-5970	20060329
	AU 2007203462	A1	20070816	AU 2007-203462	20070725
	AU 2007203463	A1	20070816	AU 2007-203463	20070725
PRAI	GB 2002-2873	A	20020207		
	AU 2003-244444	A3	20030206		
	CN 2003-803556	A3	20030206		
	WO 2003-EP1188	W	20030206		
OS	MARPAT 139:180080				
AB	The present invention relates to a process for the preparation of the title compds., amides I [R ₁ , R ₂ , R ₃ , R ₄ , R ₅ = lower alkyl, amino, lower alkoxy carbonyl, unsubstituted or substituted radical selected from benzylamino, benzoylamino, pyrrolidinyl, piperazinyl, 4-methylpiperazinyl, H, cyano, etc., with substituents selected from cyano, lower alkyl, CF ₃ , halogen, etc.; R ₁ R ₂ or R ₂ R ₃ or R ₃ R ₄ or R ₄ R ₅ = substituted or unsubstituted alkylene radical with 4 carbons, substituents = cyano, hydroxy, 4-methylpiperazinyl-substituted lower alkyl, etc. while the other three radicals are independently H, cyano, hydroxy, CF ₃ , etc.; R ₆ , R ₇ , or R ₈ = halogen, NH ₂ , NO ₂ , NHCOCF ₃ , NHCOMe, NHC(NH)NH ₂ while the other two radicals are H, lower alkyl, lower fluorinated alkyl, benzyl, Ph, Me]. For example, benzamide II was prepared by reacting 4-(3-pyridyl)-2-pyridineamine with N-(3-bromo-4-methylphenyl)-4-(4-methylpiperazin-1-				

ylmethyl)benzamide, which was prepared by condensing 3-bromo-4-methylaniline and 4-(4-methylpiperazin-1-ylmethyl)benzoic acid Me ester in toluene in the presence of AlMe₃.


IT 581076-66-6P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of N-(pyridin-3-ylpyrimidin-2-ylaminophenyl)benzamide derivs.)

RN 581076-66-6 CAPLUS

CN Benzamide, 4-(dichloromethyl)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L10 ANSWER 34 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:591164 CAPLUS
 DN 139:149642
 TI Preparation of benzoylaminophenylaminopyrimidinylpyridines as antitumor agents
 IN Boernsen, Klaus Olaf; End, Peter; Gross, Gerhard; Pfaar, Ulrike
 PA Novartis Ag, Switz.; Novartis Pharma GmbH
 SO PCT Int. Appl., 50 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003062220	A1	20030731	WO 2003-EP613	20030122
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
	RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR				
	CA 2474104	A1	20030731	CA 2003-2474104	20030122
	EP 1470120	A1	20041027	EP 2003-731700	20030122
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003007058	A	20041228	BR 2003-7058	20030122
	JP 2005519908	T	20050707	JP 2003-562099	20030122
	CN 1646519	A	20050727	CN 2003-802708	20030122
	EP 1783126	A2	20070509	EP 2007-101787	20030122
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, SE, SI, SK, TR, RO				
	IN 2004CN01599	A	20060224	IN 2004-CN1599	20040720
	MX 2004PA07130	A	20041029	MX 2004-PA7130	20040723
	US 2005209452	A1	20050922	US 2005-502291	20050429
PRAI	GB 2002-1508	A	20020123		
	EP 2003-731700	A3	20030122		
	WO 2003-EP613	W	20030122		

OS MARPAT 139:149642
 AB Title compds. I [R1 = , OH; R2 = H, alkyl, hydroxyalkyl; A = NR3R4, CR3R4, OR3R4; R3R4 = (un)substituted alkylene, oxaalkylene, azaalkylene; at least one N atom is substituted by O] were prepared for use as antitumor agents (no data). Thus, I [R1 = H, R2 = Me, A = 4-methyl-4-oxido-1-piperazinyl] was prepared by oxidation of I [R1 = H, R2 = Me, A = 4-methyl-1-piperazinyl].
 IT 152459-94-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of benzoylaminophenylaminopyrimidinylpyridines as antitumor agents)
 RN 152459-94-4 CAPLUS
 CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




IT 180258-56-4P 571187-02-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of benzoylaminophenylaminopyrimidinylpyridines as antitumor agents)


RN 180258-56-4 CAPLUS

CN Benzamide, N-[4-methyl-3-[(4-(1-oxido-3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 571187-02-5 CAPLUS

CN Benzamide, 4-(chloromethyl)-N-[4-methyl-3-[(4-(1-oxido-3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 35 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:551338 CAPLUS
 DN 139:111702
 TI Compositions and methods using ATP-dependent γ -secretase modulators for prevention and treatment of amyloid- β peptide-related disorders, and screening methods for modulators of A β
 IN Netzer, William J.; Greengard, Paul; Xu, Huaxi
 PA The Rockefeller University, USA
 SO PCT Int. Appl., 142 pp.
 CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003057165	A2	20030717	WO 2003-US249	20030106
	WO 2003057165	A3	20031113		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003206397	A1	20030724	AU 2003-206397	20030106
	US 2004028673	A1	20040212	US 2003-337261	20030106
	EP 1469810	A2	20041027	EP 2003-703695	20030106
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005522417	T	20050728	JP 2003-557524	20030106
PRAI	US 2002-345009P	P	20020104		
	WO 2003-US249	W	20030106		

OS MARPAT 139:111702

AB The invention provides methods and compns. for modulating levels of amyloid- β peptide (A β) exhibited by cells or tissues. The invention also provides pharmaceutical compns. and methods of screening for compds. that modulate A β levels. The invention also provides modulation of A β levels via selective modulation (e.g., inhibition) of ATP-dependent γ -secretase activity. The invention also provides methods of preventing, treating or ameliorating the symptoms of a disorder, including but not limited to an A β -related disorder, by administering a modulator of γ -secretase, including, but not limited to, a selective inhibitor of ATP-dependent γ -secretase activity or an agent that decreases the formation of active (or optimally active) γ -secretase. The invention also provides the use of inhibitors of ATP-dependent γ -secretase activity to prevent, treat or ameliorate the symptoms of Alzheimer's disease.


IT 560070-08-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ATP-dependent enzyme modulators for prevention and treatment of amyloid- β peptide-related disorders, and screening methods for modulators of A β)

RN 560070-08-8 CAPLUS

CN Benzamide, 4-[(4-hydroxy-1-piperazinyl)methyl]-N-[3-methyl-4-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2002:889028 CAPLUS
 DN 137:379974
 TI Pyridylpyrimidine derivatives as effective compounds against prion diseases
 IN Stein-Gerlach, Matthias; Salassidis, Konstadinos; Bacher, Gerald; Mueller, Stefan
 PA Axxima Pharmaceuticals A.-G., Germany
 SO PCT Int. Appl., 96 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002093164	A2	20021121	WO 2002-EP5420	20020516
	WO 2002093164	A3	20030904		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2446939	C	20021121	CA 2002-2446939	20020516
	CA 2446939	A1	20021121		
	AU 2002342878	A1	20021125	AU 2002-342878	20020516
	EP 1395261	A2	20040310	EP 2002-769490	20020516
	EP 1395261	B1	20060628		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
AT 331519	T	20060715	AT 2002-769490	20020516	
EP 1721609	A2	20061115	EP 2006-13237	20020516	
EP 1721609	A3	20070131			
R:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
US 2003176443	A1	20030918	US 2002-204041	20020816	
US 2006217404	A1	20060928	US 2006-350410	20060208	
PRAI	EP 2001-111858	A	20010516		
	US 2001-293528P	P	20010529		
	EP 2001-117113	A	20010713		
	US 2001-305898P	P	20010718		
	EP 2002-769490	A3	20020516		
	WO 2002-EP5420	W	20020516		
	US 2002-204041	B1	20020816		

OS MARPAT 137:379974
 AB The present invention relates to pyridylpyrimidine derivs. of the general formula (I) : wherein R represents hydrogen or Me and Z represents nitrogen containing functional groups, the use of the pyridylpyrimidine derivs. as pharmaceutically active agents, especially for the prophylaxis and/or treatment of prion infections and prion diseases, as well as compns. containing at least one pyridylpyrimidine derivative and/or pharmaceutically acceptable salt thereof. Furthermore, the present invention is directed to methods for preventing and/or treating prion infections and prion diseases using said pyridylpyrimidine derivs. Human cellular protein kinases, phosphatases and cellular signal transduction mols. are disclosed

as targets for detecting, preventing and/or treating prion infections and diseases, especially BSE, vCJD, or CJD, which can be inhibited by the inventive pyridylpyrimidine derivs.


IT 152459-76-2 152459-86-4 152459-88-6
 152459-91-1 152459-92-2 152459-94-4
 152459-96-6 152459-98-8 152459-99-9
 404844-11-7 475587-06-5 475587-08-7
 475587-09-8 475587-12-3 475587-13-4
 475587-14-5 475587-15-6 475587-18-9
 475587-19-0 475587-25-8 475587-26-9
 475587-27-0 475587-29-2 475587-31-6
 475587-32-7 475587-34-9 475587-38-3
 475587-40-7 475587-41-8 475587-42-9
 475587-43-0 475587-44-1 475587-46-3
 475587-47-4 475587-48-5 475587-49-6
 475587-50-9 475587-57-6 475587-58-7
 475587-59-8 475587-60-1 475587-62-3
 475587-63-4 475587-64-5 475587-72-5
 475587-73-6 475587-74-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pyridylpyrimidine derivs. as effective compds. against prion diseases)


RN 152459-76-2 CAPLUS

CN Benzamide, 4-chloro-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 152459-86-4 CAPLUS

CN Benzamide, 2-methoxy-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 152459-88-6 CAPLUS


CN Benzamide, 4-cyano-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 152459-91-1 CAPLUS

CN Benzamide, 4-methyl-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)


RN 152459-92-2 CAPLUS

CN Benzamide, 4-chloro-N-[3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)

RN 152459-94-4 CAPLUS


CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
(CA INDEX NAME)

RN 152459-96-6 CAPLUS


CN Benzamide, 4-methyl-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)

RN 152459-98-8 CAPLUS


CN Benzamide, 4-chloro-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)




RN 152459-99-9 CAPLUS
 CN Benzamide, 2-methoxy-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 404844-11-7 CAPLUS
 CN Benzamide, 4-(chloromethyl)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 475587-06-5 CAPLUS
 CN Benzamide, 4-(chloromethyl)-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-08-7 CAPLUS
 CN Benzamide, 3,4,5-trimethoxy-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-09-8 CAPLUS
 CN Benzamide, 4-methoxy-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 475587-12-3 CAPLUS
 CN Benzamide, 3,5-dimethoxy-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-13-4 CAPLUS
 CN Benzamide, 3,4,5-trimethoxy-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-14-5 CAPLUS
 CN Benzamide, 4-cyano-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-15-6 CAPLUS
 CN Benzamide, 4-methoxy-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-18-9 CAPLUS
 CN Benzamide, 3,5-dimethoxy-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-19-0 CAPLUS
 CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 475587-25-8 CAPLUS
 CN Benzamide, 3,4,5-trimethoxy-N-[4-methyl-3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-26-9 CAPLUS
 CN Benzamide, 4-cyano-N-[4-methyl-3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-27-0 CAPLUS
 CN Benzamide, 4-chloro-N-[4-methyl-3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-29-2 CAPLUS
 CN Benzamide, 4-cyano-N-[4-methyl-3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 475587-31-6 CAPLUS
 CN Benzamide, 4-methoxy-N-[4-methyl-3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-32-7 CAPLUS
 CN Benzamide, 4-chloro-N-[4-methyl-3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-34-9 CAPLUS

CN Benzamide, 3,5-dimethoxy-N-[3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-38-3 CAPLUS

CN Benzamide, N-[4-methyl-3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 475587-40-7 CAPLUS

CN Benzamide, 4-methoxy-N-[3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-41-8 CAPLUS

CN Benzamide, 4-cyano-N-[3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-42-9 CAPLUS


CN Benzamide, 3,4,5-trimethoxy-N-[3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-43-0 CAPLUS
 CN Benzamide, 3,5-dimethoxy-N-[4-methyl-3-[(4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-44-1 CAPLUS
 CN Benzamide, 3,4,5-trimethoxy-N-[4-methyl-3-[(4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-46-3 CAPLUS
 CN Benzamide, 4-methoxy-N-[4-methyl-3-[(4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-47-4 CAPLUS
 CN Benzamide, 3,5-dimethoxy-N-[4-methyl-3-[(4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-48-5 CAPLUS
 CN Benzamide, N-[3-[(4-(4-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-49-6 CAPLUS
 CN Benzamide, 4-chloro-N-[3-[(4-(2-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-50-9 CAPLUS
 CN Benzamide, 4-methoxy-N-[3-[(4-(2-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-57-6 CAPLUS
 CN Benzamide, 4-cyano-N-[3-[(4-(2-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-58-7 CAPLUS
 CN Benzamide, 3,5-dimethoxy-N-[3-[(4-(2-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-59-8 CAPLUS
 CN Benzamide, 4-bromo-N-[3-[(4-(2-pyridinyl)-2-pyrimidinyl)amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 475587-60-1 CAPLUS
 CN Benzamide, 4-methyl-N-[3-[(4-(2-pyridinyl)-2-pyrimidinyl)amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 475587-62-3 CAPLUS
 CN Benzamide, 3,5-dichloro-N-[3-[(4-(2-pyridinyl)-2-pyrimidinyl)amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 475587-63-4 CAPLUS
 CN Benzamide, N-[3-[(4-(2-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA
 INDEX NAME)




RN 475587-64-5 CAPLUS
 CN Benzamide, 4-(chloromethyl)-N-[3-[(4-(2-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-72-5 CAPLUS
 CN Benzamide, 2-methoxy-N-[3-[(4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 475587-73-6 CAPLUS
 CN Benzamide, N-[3-[(4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 475587-74-7 CAPLUS
 CN Benzamide, 4-methyl-N-[3-[(4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




L10 ANSWER 37 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2002:220573 CAPLUS
 DN 136:247605
 TI N-phenyl-2-pyrimidinamine derivatives as tyrosine kinase inhibitors
 IN Buerger, Hans Michael; Caravatti, Giorgio; Zimmermann, Juerg; Manley, Paul
 William; Breitenstein, Werner; Cudd, Margaret Amelia
 PA Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft
 m.b.H.
 SO PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002022597	A1	20020321	WO 2001-EP10503	20010911
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2416274	A1	20020321	CA 2001-2416274	20010911
	AU 2002018167	A5	20020326	AU 2002-18167	20010911
	BR 2001013838	A	20030603	BR 2001-13838	20010911
	EP 1322634	A1	20030702	EP 2001-984640	20010911
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004509111	T	20040325	JP 2002-526850	20010911
	CN 1525967	A	20040901	CN 2001-815539	20010911
	CN 1872850	A	20061206	CN 2006-10100258	20010911
	US 2004102453	A1	20040527	US 2003-363841	20030310
	US 7081532	B2	20060725		
	US 2006223818	A1	20061005	US 2006-448649	20060607
PRAI	GB 2000-22438	A	20000913		
	CN 2001-815539	A3	20010911		
	WO 2001-EP10503	W	20010911		
	US 2003-363841	A3	20030310		
OS	MARPAT 136:247605				
AB	The N-phenyl-2-pyrimidinamines I [R = substituted Ph; R1 = (un)substituted pyrazinyl, 1-methylpyrrolyl, aminophenyl, aminoalkylphenyl, indolyl, imidazolyl, pyridyl, pyridyl N-oxide; R2, R3 = H, alkyl] were prepared for use as tyrosine kinase inhibitors with IC50 of 3-300 nM. Thus, the benzamide II [R4 = 4-ethylpiperazino] was prepared from II [R4 = Cl] and 1-ethylpiperazine.				
IT	404844-10-6 404844-11-7				
	RL: RCT (Reactant); RACT (Reactant or reagent) (preparation of N-phenyl-2-pyrimidinamine derivs. as tyrosine kinase inhibitors)				
RN	404844-10-6 CAPLUS				
CN	Benzamide, 4-(chloromethyl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)				




● HCl


RN 404844-11-7 CAPLUS
 CN Benzamide, 4-(chloromethyl)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)



IT 404843-95-4P 404843-96-5P 404844-04-8P
 404844-05-9P 404844-06-0P 404844-07-1P
 404844-08-2P 404844-09-3P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-phenyl-2-pyrimidinamine derivs. as tyrosine kinase inhibitors)
 RN 404843-95-4 CAPLUS
 CN Benzamide, 4-[{(diethylamino)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 404843-96-5 CAPLUS
 CN Benzamide, 4-[{(dimethylamino)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 404844-04-8 CAPLUS

CN Benzamide, 3-(dimethylamino)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 404844-05-9 CAPLUS

CN Benzamide, 4-(dimethylamino)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 404844-06-0 CAPLUS

CN Benzamide, 4-(acetylamino)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 404844-07-1 CAPLUS

CN Benzamide, 3-(acetylamino)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 404844-08-2 CAPLUS

CN Benzamide, 3-hydroxy-4-methyl-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 404844-09-3 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 38 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2000:133467 CAPLUS
 DN 132:175828
 TI Method using phthalazine derivatives for treating ocular neovascular diseases
 IN Brazzell, Romulus Kimbro; Wood, Jeanette Marjorie; Campochiaro, Peter Anthony; Kane, Frances Elizabeth
 PA Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
 SO PCT Int. Appl., 30 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000009098	A2	20000224	WO 1999-EP5876	19990811
	WO 2000009098	A3	20000518		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9957330	A	20000306	AU 1999-57330	19990811
	EP 1105136	A2	20010613	EP 1999-944371	19990811
	EP 1105136	B1	20070829		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
	JP 2002522475	T	20020723	JP 2000-564601	19990811
	TW 239243	B	20050911	TW 1999-88113778	19990812
	US 6214819	B1	20010410	US 1999-442781	19991118

PRAI US 1998-133855 A 19980813
 WO 1999-EP5876 W 19990811

OS MARPAT 132:175828


AB Phthalazines are used in the preparation of medicaments for the treatment of ocular neovascularization.

IT 152459-94-4, CGP 53716

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (phthalazine derivs. for treating ocular neovascular diseases)


RN 152459-94-4 CAPLUS

CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (CA INDEX NAME)



L10 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1999:316816 CAPLUS
 DN 131:125171
 TI Prevention of cardiac allograft arteriosclerosis by protein tyrosine kinase inhibitor selective for platelet-derived growth factor receptor
 AU Sihvola, Roope; Koskinen, Petri; Myllarniemi, Marjukka; Loubtchenkov, Michael; Hayry, Pekka; Buchdunger, Elisabeth; Lemstrom, Karl
 CS Cardiopulmonary Research Group of the Transplantation Laboratory, University of Helsinki and Helsinki University Central Hospital, Helsinki, FIN-00014, Finland
 SO Circulation (1999), 99(17), 2295-2301
 CODEN: CIRCAZ; ISSN: 0009-7322
 PB Lippincott Williams & Wilkins
 DT Journal
 LA English
 AB Background-Increased immunoreactivity of platelet-derived growth factor (PDGF)-AA, -R α , and -R β in intimal cells correlates with the development of cardiac allograft arteriosclerosis, a condition for which there is little or no current therapy. Therefore, we hypothesized that PDGF may have a rate-limiting role in the development of this disease. Methods and Results-The hypothesis was tested in a rat model of heterotopic cardiac and aortic allografts using dark agouti (AG-B4, RT1a) donors and Wistar-Furth (AG-B2, RT1u) recipients. The recipients received CGP 53716, a selective PDGF-R protein tyrosine kinase inhibitor, 50 mg • kg⁻¹ • d⁻¹, or vehicle for 60 days. Cardiac allograft recipients also received background cyclosporin A immunosuppression. Our results demonstrate that CGP 53716 significantly reduced the incidence and intensity of arteriosclerotic lesions in rat cardiac and aortic allograft recipients. When rat coronary smooth muscle cells were stimulated in vitro with PDGF-AA or -BB in the presence of interleukin-1 β or tumor necrosis factor- α , CGP 53716 significantly inhibited only AA-ligand-induced but not BB-ligand-induced replication. Concomitantly, in quant. reverse transcriptase-polymerase chain reaction, interleukin-1 β or tumor necrosis factor- α stimulation specifically upregulated the expression of PDGF-R α mRNA but not of other ligand or receptor genes in cultured smooth muscle cells. Conclusions-We conclude that a PDGF-AA/R α -dependent cycle is induced in the generation of allograft arteriosclerosis that may be inhibited by blocking of signaling downstream of PDGF-R.
 IT 152459-94-4, CGP 53716
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (prevention of cardiac allograft arteriosclerosis by protein tyrosine kinase inhibitor selective for platelet-derived growth factor receptor)
 RN 152459-94-4 CAPLUS
 CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)






RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 40 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1999:185580 CAPLUS
 DN 131:27908
 TI Inhibition of obliterative bronchiolitis by platelet-derived growth factor receptor protein-tyrosine kinase inhibitor
 AU Kallio, E.; Koskinen, P.; Buchdunger, E.; Lemstrom, K.
 CS Transplantation Laboratory, University of Helsinki, Helsinki, FIN-00014, Finland
 SO Transplantation Proceedings (1999), 31(1/2), 187
 CODEN: TRPPA8; ISSN: 0041-1345
 PB Elsevier Science Inc.
 DT Journal
 LA English
 AB The authors investigated the role of platelet-derived growth factor (PDGF) in the development of obliterative bronchiolitis and the effect of a protein-tyrosine kinase (PTK) inhibitor selective for PDGF receptors (CGP53716) on obliterative bronchiolitis in rats with tracheal transplantations. Significant upregulation of allograft PDGF-AA and α receptor expression was observed at 3 and 10 days after transplantation compared with syngeneic grafts. This study suggests a regulatory role for PDGF especially for PDGF-AA and α receptor in the development of obliterative bronchiolitis. This study also demonstrates that inhibition of PDGF receptors with protein-tyrosine kinase inhibitor significantly reduces myofibroproliferation and airway occlusion suggesting a novel therapeutic strategy for the prevention of obliterative bronchiolitis in lung transplantation.


IT 152459-94-4, CGP53716
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (inhibition of obliterative bronchiolitis by platelet-derived growth factor receptor protein-tyrosine kinase inhibitor in relation to role of platelet-derived growth factor and treatment in lung transplantation)

RN 152459-94-4 CAPLUS
 CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L10 ANSWER 41 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1999:185568 CAPLUS
 DN 131:13660
 TI Prevention of cardiac allograft arteriosclerosis by protein-tyrosine kinase inhibitor selective for platelet-derived growth factor receptor
 AU Koskinen, P.; Sihvola, R.; Myllarniemi, M.; Hayry, P.; Buchdunger, E.; Lemstrom, K.
 CS Cardiopulmonary Research Group of the Transplantation Laboratory, University of Helsinki and Helsinki University Central Hospital, Helsinki, FIN-00014, Finland
 SO Transplantation Proceedings (1999), 31(1/2), 102
 CODEN: TRPPA8; ISSN: 0041-1345
 PB Elsevier Science Inc.
 DT Journal
 LA English
 AB Increased immunoreactivity of platelet-derived growth factor (PDGF) -AA, -R α , and -R β in intimal cells correlates with the development of cardiac allograft arteriosclerosis. The results of this study conclude that PDGF-AA-R α dependent cycle is induced in the generation of allograft arteriosclerosis, which may be inhibited by blocking of signaling downstream of PDGF-R.
 IT 152459-94-4, Cgp 53716
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (prevention of cardiac allograft arteriosclerosis by protein-tyrosine kinase inhibitor selective for platelet-derived growth factor receptor)
 RN 152459-94-4 CAPLUS
 CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 42 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1997:728227 CAPLUS
 DN 128:43608
 TI Inhibition of platelet-derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferation
 AU Myllarniemi, Marukka; Calderon, Lazaro; Lemstrom, Karl; Buchdunger, Elisabeth; Hayry, Pekka
 CS Transplantation Laboratory, University of Helsinki, Helsinki, Finland
 SO FASEB Journal (1997), 11(13), 1119-1126
 CODEN: FAJOEC; ISSN: 0892-6638
 PB Federation of American Societies for Experimental Biology
 DT Journal
 LA English
 AB Platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) have been linked to vascular smooth muscle cell (SMC) migration and proliferation leading to atherosclerosis, restenosis, and chronic allograft rejection. This study describes the effect of CGP 53716, a specific PDGFR tyrosine kinase inhibitor on SMC proliferation and migration in vitro and in neointimal formation in vivo. CGP 53716 inhibited dose dependently tyrosine phosphorylation of both the known PDGFRs: the PDGFR- α and PDGFR- β . In primary rat SMC cultures, a dose-dependent inhibition of PDGF-AA and PDGF-BB induced migration, and tritiated thymidine incorporation of SMC was seen at nontoxic concns. After rat carotid artery ballooning injury in vivo, the migration of α -actin-pos. cells on the luminal side of internal elastic lamina was decreased with 50 mg \cdot kg $^{-1}$ \cdot day $^{-1}$ of CGP 53716 from 38 \pm 10 (control group) to 4 \pm 2 ($P<0.0001$, Mann-Whitney U test, N=18). CGP 53716 did not inhibit the number of replicating bromodeoxyuridine (BrdU)-incorporating cells in the intima, media, or adventitia during BrdU labeling at 0-96 postoperative h, though it inhibited significantly ($P<0.01$) the replication of medial and intimal cells from 93 h onward. Intima/media ratio was inhibited by 40% after 14 days in the CGP 53716-treated group ($P=0.028$) after rat aortic denudation. The results indicate that inhibition of the PDGFR tyrosine kinase inhibits SMC migration and proliferation in vitro, SMC migration, and, to a lesser extent, proliferation after ballooning injury in vivo, confirming a causal role for activation of the PDGFR and the formation of neointimal lesions.
 IT 152459-94-4, CGP 53716
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (PDGFR tyrosine kinase inhibitor CGF 53716 antiatherosclerotic activity)
 RN 152459-94-4 CAPLUS
 CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)

X




L10 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1997:674685 CAPLUS
 DN 127:355149
 TI Inhibition of cell growth: effects of the tyrosine kinase inhibitor CGP 53716
 AU Major, Terry C.; Keiser, Joan A.
 CS Parke-Davis Pharmaceutical Research Division, Department of Vascular and Cardiac Diseases, Warner Lambert Company, Ann Arbor, MI, USA
 SO Journal of Pharmacology and Experimental Therapeutics (1997), 283(1), 402-410
 CODEN: JPETAB; ISSN: 0022-3565
 PB Williams & Wilkins
 DT Journal
 LA English

AB The growth factors, platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF), play major roles in enhanced smooth muscle cells growth in rodent blood vessels after vascular injury. Tyrosine kinase inhibition has been shown to be effective in blocking tyrosine phosphorylation at the PDGF and bFGF receptors in cultured fibroblast and vascular smooth muscle cells which in turn inhibits their proliferation. Our study evaluated the PDGF selective tyrosine kinase inhibitor, CGP 53716, on serum, PDGF-BB, bFGF or epidermal growth factor-induced growth responses in cultured rat aortic smooth muscle cells (RASMC) and Balb/3T3 fibroblasts (3T3). CGP 53716 inhibited serum-induced cell growth in RASMC, but not in 3T3 cells. CGP 53716 completely blocked PDGF-BB tyrosine receptor autophosphorylation in RASMC and 3T3 cells, PDGF-BB-induced phosphorylation of mitogen-activated protein kinase at 1 μ M in RASMC and inhibited PDGF-BB-induced c-Fos protein expression at 1 μ M in RASMC; consistent with inhibition of PDGF-BB-induced DNA synthesis. To examine the selectivity of CGP 53716, PDGF-BB, bFGF or EGF-induced DNA synthesis was measured using thymidine incorporation. CGP 53716 inhibited PDGF-BB-, bFGF- and EGF-induced DNA synthesis in a concentration-dependent manner in each cell line. CGP 53716 showed a 2- to 4-fold selectivity for PDGF-BB-stimulated DNA synthesis over bFGF or EGF in RASMC or 3T3 cells. To rule out that bFGF induced the release of endogenous PDGF, an antibody to PDGF-AB, which binds to all three isoforms of PDGF, was coincubated with bFGF and did not suppress the DNA synthesis induced by bFGF. Based on these results, CGP 53716 is not selective for the PDGF receptor as previously reported. However, EGF-stimulated receptor autophosphorylation of mitogen-activated protein kinase phosphorylation and c-Fos protein expression were not inhibited by CGP 53716 at 1 or 10 μ M in RASMC. The findings suggest that CGP 53716 may inhibit multiple growth factor pathways as indicated by inhibition of DNA synthesis. However, these effects must be downstream from the signaling for c-Fos protein expression or use an alternate signaling route. These results further suggest that CGP 53716 may have a therapeutic potential for the treatment of vascular proliferative diseases which are stimulated by not only PDGF but other growth factors such as bFGF and EGF.

IT 152459-94-4, CGP 53716
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (tyrosine kinase inhibitor CGP 53716 inhibition of vascular smooth muscle cell growth)

RN 152459-94-4 CAPLUS
 CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 44 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1997:617993 CAPLUS
 DN 127:272793
 TI Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds
 IN Muller, Marcel; Geiger, Thomas; Altmann, Karl-Heinz; Fabbro, Doriano; Monia, Brett
 PA Novartis AG, Switz.
 SO PCT Int. Appl., 118 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9732604	A1	19970912	WO 1997-EP875	19970224
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9720925	A	19970922	AU 1997-20925	19970224
	ZA 9701936	A	19970908	ZA 1997-1936	19970306
PRAI	US 1996-612787	A	19960307		
	WO 1997-EP875	W	19970224		

AB The invention relates to combinations of raf-targeted (especially c-raf-targeted) deoxyribo- and ribo-oligonucleotides and derivs. thereof with other chemotherapeutic compds., as well as to pharmaceutical preps. and/or therapies, in relation to disease states which respond to such oligonucleotides or oligonucleotide derivs., especially to modulation of the activity of a regulatory protein. In particular, the invention relates to products or combinations comprising antisense oligonucleotides or oligonucleotide derivs. targeted to nucleic acids encoding raf and other (preferably standard) chemotherapeutics, either in fixed combination or for chronol. staggered or simultaneous administration, and the combined use of both classes of compds., either in fixed combination or for chronol. staggered or simultaneous administration, for the treatment of proliferative diseases, especially tumor diseases, that can be treated by inhibition of raf activity, i.e., where the antisense oligonucleotides or oligonucleotide derivs. are targeted to nucleic acids encoding the regulatory protein raf or active mutated derivs. thereof.


IT 152459-94-4
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (raf-targeted oligonucleotide-chemotherapeutic compound antiproliferative combinations)

RN 152459-94-4 CAPLUS


CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (CA INDEX NAME)




L10 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1997:123312 CAPLUS
 DN 126:220297
 TI Potent and selective inhibitors of the ABL-kinase: phenylaminopyrimidine (PAP) derivatives
 AU Zimmermann, Jurg; Buchdunger, Elisabeth; Mett, Helmut; Meyer, Thomas;
 Lydon, Nicholas B.
 CS Ciba Pharmaceuticals Division, Oncology Research Department, Ciba-Geigy Limited, Basel, CH-4002, Switz.
 SO Bioorganic & Medicinal Chemistry Letters (1997), 7(2), 187-192
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier
 DT Journal
 LA English
 AB Due to its relatively clear etiol., chronic myelogenous leukemia (CML) represents an ideal disease target for a therapy using a selective inhibitor of the Bcr-Abl tyrosine protein kinase. Extensive optimization of the class of phenylamino-pyrimidines yielded highly potent and selective Bcr-Abl kinase inhibitors. X
 IT 152459-77-3P 152459-82-0P 152459-86-4P
 152459-87-5P 152459-88-6P 152459-91-1P
 152459-94-4P 152459-96-6P 152459-98-8P
 152459-99-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of phenylaminopyrimidine derivs. as inhibitors of ABL-kinase)
 RN 152459-77-3 CAPLUS
 CN Benzamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-82-0 CAPLUS
 CN Benzoic acid, 2-[[[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 152459-86-4 CAPLUS
 CN Benzamide, 2-methoxy-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-87-5 CAPLUS
 CN Benzamide, 4-fluoro-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 152459-88-6 CAPLUS
 CN Benzamide, 4-cyano-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 152459-91-1 CAPLUS
 CN Benzamide, 4-methyl-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 152459-94-4 CAPLUS
 CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-
 (CA INDEX NAME)




RN 152459-96-6 CAPLUS
 CN Benzamide, 4-methyl-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 152459-98-8 CAPLUS
 CN Benzamide, 4-chloro-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-99-9 CAPLUS
 CN Benzamide, 2-methoxy-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 46 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1996:495435 CAPLUS
 DN 125:184908
 TI Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC)
 AU Zimmermann, Juerg; Caravatti, Giorgio; Mett, Helmut; Meyer, Thomas;
 Mueller, Marcel; Lydon, Nicholas B.; Fabbro, Doriano
 CS CIBA Pharmaceuticals Div., Oncology Virology Res. Dep., Ciba-Geigy Limited, Basel, CH-4002, Switz.
 SO Archiv der Pharmazie (Weinheim, Germany) (1996), 329(7), 371-376
 CODEN: ARPMA; ISSN: 0365-6233
 PB VCH
 DT Journal
 LA English
 OS CASREACT 125:184908
 AB Phenylamino-pyrimidines represent a novel class of inhibitors of protein kinase C with a high degree of selectivity vs. other serine/threonine and tyrosine kinases. Steady state kinetic anal. of N-(3-[1-imidazolyl]-phenyl)-4-(3-pyridyl)-2-pyrimidinamine , which showed potent inhibitory activity, revealed competitive kinetics relative to ATP. The adjacent H-bond acceptor of the pyrimidine moiety next to an H-bond donor of the phenylamine was found to be crucial for inhibitory activity. N-(3-Nitro-phenyl)-4-(3-pyridyl)-2-pyrimidinamine preferentially inhibited PKC- α ($IC_{50} = 0.79 \mu M$) and not the other subtypes tested. The inhibition consts. of PKC- α and the antiproliferative effect on T24 human bladder carcinoma cells showed a qual. correlation, although with some exceptions.
 IT 152459-76-2P 152459-86-4P 152459-88-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of phenylamino-pyrimidine derivs. as a new class of potent and selective inhibitors of protein kinase C)
 RN 152459-76-2 CAPLUS
 CN Benzamide, 4-chloro-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-86-4 CAPLUS
 CN Benzamide, 2-methoxy-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-88-6 CAPLUS

CN Benzamide, 4-cyano-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)




L10 ANSWER 47 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1996:380210 CAPLUS
 DN 125:114681
 TI Pyrimidine derivatives and processes for the preparation thereof
 IN Zimmermann, Juerg
 PA Ciba-Geigy Corporation, USA
 SO U.S., 18 pp., Cont.-in-part of U.S. Ser. No. 42,322, abandoned.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 3


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5521184 CA 2148477	A A1	19960528 19950413	US 1994-234889 CA 1994-2148477	19940428 19940921
PRAI	CH 1992-1083 US 1993-42322 CH 1993-2966	A B2 A	19920403 19930402 19931001		
OS	MARPAT 125:114681				
AB	There are described N-phenyl-2-pyrimidine-amine derivs. (I) wherein R1 is 4-pyrazinyl, 1-methyl-1H-pyrrolyl, amino- or amino-lower alkyl-substituted Ph wherein the amino group in each case is free, alkylated or acylated, 1H-indolyl or 1H-imidazolyl bonded at a five-membered ring carbon atom, or unsubstituted or lower alkyl-substituted pyridyl bonded at a ring carbon atom and unsubstituted or substituted at the nitrogen atom by oxygen; R2 and R3 are hydrogen or lower alkyl; one or two of R4, R5, R6, R7 are each nitro, fluoro-substituted lower alkoxy or -N(R9)C(:X)(Y)nR10. These compds. can be used, for example, in the therapy of tumoral diseases. Three example formulations are given.				
IT	179115-22-1				
	RL: RCT (Reactant); RACT (Reactant or reagent) (for preparation of phenylaminopyrimidine derivs. as antitumor agents)				
RN	179115-22-1 CAPLUS				
CN	Benzamide, N-[3-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				




IT 152459-76-2P 152459-77-3P 152459-81-9P
 152459-82-0P 152459-86-4P 152459-87-5P
 152459-88-6P 152459-91-1P 152459-92-2P
 152459-94-4P 152459-96-6P 152459-98-8P
 152459-99-9P 152460-05-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of phenylaminopyrimidine derivs. as antitumor agents)
 RN 152459-76-2 CAPLUS
 CN Benzamide, 4-chloro-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)




RN 152459-77-3 CAPLUS
 CN Benzamide, N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-81-9 CAPLUS
 CN Benzamide, 2,3,4,5,6-pentafluoro-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-82-0 CAPLUS
 CN Benzoic acid, 2-[[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]amino]carbonyl- (9CI) (CA INDEX NAME)




RN 152459-86-4 CAPLUS
 CN Benzamide, 2-methoxy-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-87-5 CAPLUS
 CN Benzamide, 4-fluoro-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 152459-88-6 CAPLUS
 CN Benzamide, 4-cyano-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 152459-91-1 CAPLUS
 CN Benzamide, 4-methyl-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 152459-92-2 CAPLUS
 CN Benzamide, 4-chloro-N-[3-[(4-(4-pyridinyl)-2-pyrimidinyl)amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 152459-94-4 CAPLUS
 CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (CA INDEX NAME)




RN 152459-96-6 CAPLUS
 CN Benzamide, 4-methyl-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-98-8 CAPLUS
 CN Benzamide, 4-chloro-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-99-9 CAPLUS
 CN Benzamide, 2-methoxy-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152460-05-4 CAPLUS
 CN Benzamide, N-[3-methyl-5-[[4-(1-oxido-3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1996:368753 CAPLUS
 DN 125:167896
 TI (Phenylamino)pyrimidine (PAP) derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors
 AU Zimmermann, Juerg; Buchdunger, Elisabeth; Mett, Helmut; Meyer, Thomas; Lydon, Nicholas B.; Traxler, Peter
 CS Oncol. Res. Dep., Ciba Pharm. Div., Basel, CH-4002, Switz.
 SO Bioorganic & Medicinal Chemistry Letters (1996), 6(11), 1221-1226
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier
 DT Journal
 LA English
 AB (Phenylamino)pyrimidines represent a novel class of inhibitors of the PDGF-receptor autophosphorylation with a high degree of selectivity vs. other tyrosine and serine/threonine kinases. Optimum activity of ca 10 nM (IC₅₀) was observed when the phenylamino-group which is attached to the pyrimidine carries a benzamide-moiety with a lipophilic substituent in 4-position. The target compds. were derivs. of 4-methyl-N³-[4-(3-pyridinyl)-2-pyrimidinyl]-1,3-benzenediamine I (R₂ = H, Me; R₃ = H, benzoyl, Me, etc.; R₄ = H, benzoyl, etc.). A 2-thienyl analog of I was also prepared and tested.
 IT 152459-77-3P 152459-94-4P 152459-96-6P
 152459-98-8P 152459-99-9P 180258-56-4P
 180258-58-6P 180258-59-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of [(pyridinyl)pyrimidinyl]benzenediamines as tyrosine kinase or serine/threonine kinase inhibitors)
 RN 152459-77-3 CAPLUS
 CN Benzamide, N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-94-4 CAPLUS
 CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)




RN 152459-96-6 CAPLUS

CN Benzamide, 4-methyl-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-98-8 CAPLUS

CN Benzamide, 4-chloro-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-99-9 CAPLUS

CN Benzamide, 2-methoxy-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 180258-56-4 CAPLUS

CN Benzamide, N-[4-methyl-3-[[4-(1-oxido-3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 180258-58-6 CAPLUS

CN Benzamide, N-[4-chloro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 180258-59-7 CAPLUS

CN Benzamide, N-[4-methoxy-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-
(9CI) (CA INDEX NAME)




L10 ANSWER 49 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1995:909361 CAPLUS
 DN 123:313996
 TI Preparation of N-phenyl-2-pyrimidineamine antitumor agents
 IN Zimmermann, Juerg
 PA Ciba-Geigy A.-G., Switz.
 SO PCT Int. Appl., 69 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9509847	A1	19950413	WO 1994-EP3150	19940921
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ, VN RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2148931	A1	19950413	CA 1993-2148931	19930921
	AU 9476976	A	19950501	AU 1994-76976	19940921
	AU 693475	B2	19980702		
	EP 672035	A1	19950920	EP 1994-927634	19940921
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE JP 08503971 T 19960430 JP 1994-510577 19940921				
	US 5612340 A 19970318 US 1995-436345 19950517				
PRAI	CH 1993-2967	A	19931001		
	CH 1994-2279	A	19940718		
	WO 1994-EP3150 W 19940921				
OS	MARPAT 123:313996				
AB	N-phenyl-2-pyrimidineamine derivs. [I; R1 = naphthyl, fluorenyl, anthracenyl, (un)substituted cyclic residue, etc.; R2 = NO ₂ , F-substituted lower alkoxy, etc.] [e.g., N-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-4-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine; m.p. 132°], useful for the treatment of tumor diseases (no data), are prepared and I-containing formulations presented.				
IT	170141-43-2P				
	RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of N-phenyl-2-pyrimidineamine antitumor agents)				
RN	170141-43-2 CAPLUS				
CN	Benzamide, N-[3-[(4-[(2-aminoethyl)amino]-4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				



L10 ANSWER 50 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1995:479796 CAPLUS
 DN 122:230302
 TI Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class
 AU Buchdunger, Elisabeth; Zimmermann, Juerg; Mett, Helmut; Meyer, Thomas; Mueller, Marcel; Regenass, Urs; Lydon, Nicholas B.
 CS Oncology Research Department, CIBA-Geigy Limited, Basel, CH-4002, Switz.
 SO Proceedings of the National Academy of Sciences of the United States of America (1995), 92(7), 2558-62
 CODEN: PNASA6; ISSN: 0027-8424
 PB National Academy of Sciences
 DT Journal
 LA English
 AB The platelet-derived growth factor (PDGF) receptor is a member of the transmembrane growth factor receptor protein family with intrinsic protein-tyrosine kinase activity. The authors described a potent protein-tyrosine kinase inhibitor (CGP 53716) that shows selectivity for the PDGF receptor *in vitro* and *in the cell*. The compound shows selectivity for inhibition of PDGF-mediated events such as PDGF receptor autophosphorylation, cellular tyrosine phosphorylation, and c-fos mRNA induction in response to PDGF stimulation of intact cells. In contrast, ligand-induced autophosphorylation of the epidermal growth factor (EGF) receptor, insulin receptor, and the insulin-like growth factor I receptor, as well as c-fos mRNA expression induced by EGF, fibroblast growth factor, and phorbol ester, was insensitive to inhibition by CGP 53716. In antiproliferative assays, the compound was \approx 30-fold more potent in inhibiting PDGF-mediated growth of v-sis-transformed BALB/c 3T3 cells relative to inhibition of EGF-dependent BALB/MK cells, interleukin-3-dependent FDC-P1 cells, and the T24 bladder carcinoma line. When tested *in vivo* using highly tumorigenic v-sis- and human c-sis-transformed BALB/c 3T3 cells, CGP 53716 showed antitumor activity at well-tolerated doses. In contrast, CGP 53716 did not show antitumor activity against xenografts of the A431 tumor, which overexpresses the EGF receptor. These findings suggest that CGP 53716 may have therapeutic potential for the treatment of diseases involving abnormal cellular proliferation induced by PDGF receptor activation.
 IT 152459-94-4
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (phenylaminopyrimidine derivative as inhibitor of platelet-derived growth factor receptor tyrosine kinase)
 RN 152459-94-4 CAPLUS
 CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (CA INDEX NAME)



L10 ANSWER 51 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1994:107056 CAPLUS
 DN 120:107056
 TI Preparation of 2-anilinopyrimidines as antiatherosclerotics and neoplasm inhibitors
 IN Zimmermann, Juerg
 PA Ciba-Geigy A.-G., Switz.
 SO Eur. Pat. Appl., 23 pp.
 CODEN: EPXXDW

DT Patent
 LA German

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 564409	A1	19931006	EP 1993-810219	19930325
	EP 564409	B1	20000119		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	AT 188964	T	20000215	AT 1993-810219	19930325
	ES 2142857	T3	20000501	ES 1993-810219	19930325
	PT 564409	T	20000630	PT 1993-810219	19930325
	FI 109534	B1	20020830	FI 1993-1458	19930331
	CA 2093203	A1	19931004	CA 1993-2093203	19930401
	CA 2093203	C	20021126		
	CZ 283944	B6	19980715	CZ 1993-560	19930401
	RU 2125992	C1	19990210	RU 1993-5357	19930401
	IL 105264	A	19990411	IL 1993-105264	19930401
	SK 280620	B6	20000516	SK 1993-280	19930401
	NO 9301283	A	19931004	NO 1993-1283	19930402
	NO 302473	B1	19980309		
	ZA 9302397	A	19931004	ZA 1993-2397	19930402
	AU 9335694	A	19931007	AU 1993-35694	19930402
	AU 666709	B2	19960222		
	CN 1077713	A	19931027	CN 1993-103566	19930402
	CN 1043531	B	19990602		
	HU 64050	A2	19931129	HU 1993-982	19930402
	JP 06087834	A	19940329	JP 1993-78096	19930405
	JP 2706682	B2	19980128		
	GR 3032927	T3	20000731	GR 2000-400623	20000310
PRAI	CH 1992-1083	A	19920403		

OS MARPAT 120:107056


AB Title compds. [I; R1 = pyridyl, 4-pyrazinyl, (acyl)aminophenyl, etc.; R2, R3 = H, alkyl; 1 or 2 of R4-R8 = NO₂, fluoroalkoxy, NR₉C(:X)Y_nR₁₀ and the others = H, alkyl, alkanoyl, CF₃, etc.; R9 = H, alkyl; R10 = (cyclo)aliphatic group, heterocyclyl, aryl, etc.; X = O, S, NH, etc.; Y = O or NH; n = 0 or 1] were prepared. Thus, 3-(O₂N)C₆H₄NHC(:NH)NH₂ [preparation from 3-(O₂N)C₆H₄NH₂ given] was cyclocondensed with R₁COCH:CHNMe₂ (R₁ = 3-pyridyl) (preparation from 3-acetylpyridine given) to give I (R₁ = 3-pyridyl, R₂ = R₃ = R₅-R₈ = H, R₄ = NO₂). I had IC₅₀ of .apprx.0.5 to 5 μM against protein kinase C in vitro.

IT 152459-76-2P 152459-77-3P 152459-81-9P
 152459-82-0P 152459-86-4P 152459-87-5P
 152459-88-6P 152459-91-1P 152459-92-2P
 152459-94-4P 152459-96-6P 152459-98-8P
 152459-99-9P 152460-05-4P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as antiatherosclerotic and neoplasm inhibitor)

RN 152459-76-2 CAPLUS


CN Benzamide, 4-chloro-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 152459-77-3 CAPLUS
 CN Benzamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-81-9 CAPLUS
 CN Benzamide, 2,3,4,5,6-pentafluoro-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-82-0 CAPLUS
 CN Benzoic acid, 2-[[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]amino]carbonyl- (9CI) (CA INDEX NAME)




RN 152459-86-4 CAPLUS
 CN Benzamide, 2-methoxy-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-87-5 CAPLUS
 CN Benzamide, 4-fluoro-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 152459-88-6 CAPLUS
 CN Benzamide, 4-cyano-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 152459-91-1 CAPLUS
 CN Benzamide, 4-methyl-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (9CI) (CA INDEX NAME)



RN 152459-92-2 CAPLUS
 CN Benzamide, 4-chloro-N-[3-[(4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 152459-94-4 CAPLUS

CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
(CA INDEX NAME)


RN 152459-96-6 CAPLUS

CN Benzamide, 4-methyl-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-98-8 CAPLUS

CN Benzamide, 4-chloro-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-99-9 CAPLUS

CN Benzamide, 2-methoxy-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 152460-05-4 CAPLUS

CN Benzamide, N-[3-methyl-5-[(4-(1-oxido-3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



10/528,913

=> log y COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	269.71	490.32
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-39.78	-39.78

STN INTERNATIONAL LOGOFF AT 02:52:58 ON 01 OCT 2007